# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from to  Commission File Number  State or other jurisdiction of incorporation or organization  SAIC, Inc.  1710 SAIC Drive, McLean, Virginia 22102 (703) 676-4300  Science Applications	I.R.S. Employer Identification No. 20-3562868
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from to  Commission File Number  State or other jurisdiction of incorporation or organization  SAIC, Inc.  1710 SAIC Drive, McLean, Virginia 22102 (703) 676-4300  Science Applications	Employer Identification No.
Commission File Number  State or other jurisdiction of incorporation or organization  State or other jurisdiction of incorporation or organization  SAIC, Inc.  1710 SAIC Drive, McLean, Virginia 22102 (703) 676-4300  Science Applications	Employer Identification No.
Commission File Number  Exact Name of Registrant as Specified in its Charter, Address of Principal Executive Offices and Telephone Number  SAIC, Inc.  1710 SAIC Drive, McLean, Virginia 22102 (703) 676-4300  Science Applications	Employer Identification No.
Commission File Number  SAIC, Inc.  1710 SAIC Drive, McLean, Virginia 22102 (703) 676-4300  Science Applications	Employer Identification No.
1710 SAIC Drive, McLean, Virginia 22102 (703) 676-4300  Science Applications	20-3562868
Science Applications	
000-12771	
International Corporation Delaware	95-3630868
1710 SAIC Drive, McLean, Virginia 22102 (703) 676-4300	
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exc 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has be such filing requirements for the past 90 days.	
SAIC, Inc. Science Applications International Corporation Yes I	
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Intera required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 mor shorter period that the registrant was required to submit and post such files).	
SAIC, Inc.  Science Applications International Corporation  Yes   Yes  Yes	
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller recompany. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Excelerated filer.	
SAIC, Inc. Large accelerated filer $\square$ Accelerated filer $\square$ Non-accelerated filer $\square$ Smaller reporting com	pany
Science Applications International Corporation  Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting com	pany
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).	
SAIC, Inc. Science Applications International Corporation Yes [ Yes [	
The number of shares issued and outstanding of each issuer's classes of common stock as of November 16, 2012 was as follows:	
SAIC, Inc. 341,871,438 shares of common stock (\$.0001 par value per share) Science Applications	
International Corporation 5,000 shares of common stock (\$.01 par value per share) held by SAIC, Inc.	

### **Explanatory Note**

This Quarterly Report on Form 10-Q is a combined report being filed by SAIC, Inc. ("SAIC") and Science Applications International Corporation ("Science Applications"). SAIC is a holding company and Science Applications is a direct, 100%-owned subsidiary of SAIC. Each of SAIC and Science Applications is filing on its own behalf all of the information contained in this report that relates to such company. Where information or an explanation is provided that is substantially the same for each company, such information or explanation has been combined in this report. Where information or an explanation is not substantially the same for each company, separate information and explanation has been provided. In addition, separate condensed consolidated financial statements for each company, along with combined notes to the condensed consolidated financial statements, are included in this report. Unless indicated otherwise, references in this report to the "Company", "we", "us" and "our" refer collectively to SAIC, Science Applications and its consolidated subsidiaries.

### PART I—FINANCIAL INFORMATION

# Item 1. Financial Statements.

# SAIC, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

		Three Months Ended October 31				Nine Months Ended October 31	
	201	2	2011		2012		2011
			s, except				
Revenues	\$2,87	0 \$:	2,790	\$8	,462	\$8	3,026
Costs and expenses:							
Cost of revenues	2,50	9	2,477	7	,429	7	7,051
Selling, general and administrative expenses	15		333		429		562
Separation transaction expenses	1	1	_		15		
Operating income (loss)	19	3	(20)		589		413
Non-operating income (expense):							
Interest income		2	2		6		3
Interest expense	(2	0)	(29)		(73)		(85)
Other income (expense), net		2	(2)		8		3
Income (loss) from continuing operations before income taxes	17	7	(49)		530		334
Provision for income taxes	(6	5)	(43)		(193)		(188)
Income (loss) from continuing operations	11	2	(92)		337		146
Discontinued operations (Note 1):			. ,				
Income from discontinued operations before income taxes	_	_	4		3		127
Provision for income taxes	_	_	(1)		(1)		(53)
Income from discontinued operations	_	_	3		2		74
Net income (loss)	\$ 11	2 \$	(89)	\$	339	\$	220
Earnings per share (Note 2):			, ,				-
Basic:							
Income (loss) from continuing operations	\$ .3	3 \$	(.28)	\$	.99	\$	.42
Income from discontinued operations	_	_	`.01 <sup>´</sup>		.01		.21
·	\$ .3	3 \$	(.27)	\$	1.00	\$	.63
Diluted:			,				
Income (loss) from continuing operations	\$ .3	3 \$	(.28)	\$	.99	\$	.42
Income from discontinued operations	_	_	.01	_	.01	•	.21
	\$ .3	3 \$	(.27)	\$	1.00	\$	.63
Cash dividends paid per share	\$ .1		<u> </u>	\$	.36	\$	
Cach arracing paid por origin	Ψ 11	<u>Ψ</u>			.00	Ψ_	

# CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

		nths Ended ber 31	Nine Mon Octob	ths Ended per 31
	2012	2011	2012	2011
		(in mill	ions)	
Net income (loss)	<b>\$ 112</b>	\$ (89)	\$ 339	\$ 220
Other comprehensive income, net of tax:				
Foreign currency translation adjustments	_	_	(1)	7
Deferred taxes	_	_	1	(3)
Foreign currency translation adjustments, net of tax	_	_	_	4
Reclassification of realized loss on settled derivative instruments to net income	_	1	_	1
Deferred taxes		(1)		(1)
Reclassification of realized loss on settled derivative instruments to net income, net of tax	_	_	_	_
Pension liability adjustments	_	_	16	_
Deferred taxes	_	_	(6)	_
Pension liability adjustments, net of tax	_	_	10	_
Total other comprehensive income, net of tax	_	_	10	4
Comprehensive income (loss)	\$ 112	\$ (89)	\$ 349	\$ 224

# SAIC, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	Oc	tober 31, 2012	Ja	nuary 31, 2012
		(in m	llions)	
ASSETS				
Current assets:	_			
Cash and cash equivalents	\$	531	\$	1,592
Receivables, net		1,943		2,164
Inventory, prepaid expenses and other current assets		554		439
Assets of discontinued operations		34		36
Total current assets		3,062		4,231
Property, plant and equipment (less accumulated depreciation and amortization of \$447 million and \$424 million at				
October 31, 2012 and January 31, 2012, respectively)		319		348
Intangible assets, net		214		176
Goodwill		2,195		1,800
Deferred income taxes		_		37
Other assets		76		75
	\$	5,866	\$	6,667
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:				
Accounts payable and accrued liabilities	\$	1,291	\$	1,961
Accrued payroll and employee benefits		624		504
Income taxes payable		41		
Notes payable and long-term debt, current portion		2		553
Liabilities of discontinued operations		8		7
Total current liabilities		1,966		3,025
Notes payable and long-term debt, net of current portion		1,297		1,299
Other long-term liabilities		148		162
Commitments and contingencies (Notes 10 and 11)				
Stockholders' equity:				
Common stock, \$.0001 par value, 2 billion shares authorized, 342 million and 341 million shares issued and				
outstanding at October 31, 2012 and January 31, 2012, respectively		_		_
Additional paid-in capital		2,089		2,028
Retained earnings		367		164
Accumulated other comprehensive loss		(1)		(11)
Total stockholders' equity		2,455		2,181
···· ··· · · · · · · · · · · · · · · ·	\$	5,866	\$	

# SAIC, INC. CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)

	Shares of common	Additional paid-in			cumulated other rehensive	
	stock	capital	earnings		loss	Total
			(in millions)			
Balance at January 31, 2012	341	\$ 2,028	\$ 164	\$	(11)	\$2,181
Net income	_	_	339		_	339
Other comprehensive income, net of tax	_	_	_		10	10
Issuances of stock	2	19	_		_	19
Repurchases of stock	(1)	(10)	(11)		_	(21)
Quarterly cash dividends of \$0.12 per share		·	(125)		_	(125)
Adjustments for income tax benefits from stock-based compensation	_	(15)	· —		_	(15)
Stock-based compensation	_	67	_		_	67
Balance at October 31, 2012	342	\$ 2,089	\$ 367	\$	(1)	\$2,455

# CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Cash flows from operating activities of continuing operations:  Net income Income from discontinued operations Adjustments to reconcile net income to net cash provided by operating activities of continuing operations:  Depreciation and amortization	\$	2012 (in mill 339 (2) 85 67 2	ions)	2011 220 (74)
Net income Income from discontinued operations Adjustments to reconcile net income to net cash provided by operating activities of continuing operations:	\$	339 (2) 85 67 2	,	(74)
Net income Income from discontinued operations Adjustments to reconcile net income to net cash provided by operating activities of continuing operations:	\$	(2) 85 67 2	\$	(74)
Income from discontinued operations  Adjustments to reconcile net income to net cash provided by operating activities of continuing operations:	Ψ	(2) 85 67 2	Ψ	(74)
Adjustments to reconcile net income to net cash provided by operating activities of continuing operations:		85 67 2		` ,
		67 2		
		67 2		86
Stock-based compensation		2		64
Impairment losses				19
Net gain on sales and disposals of assets				
·		(7)		(32)
Other		3		_
Increase (decrease) in cash and cash equivalents, net of acquisitions and divestitures, resulting from changes in:		074		(0.4)
Receivables		271		(94)
Inventory, prepaid expenses and other current assets		(79)		38
Deferred income taxes		(4)		(11)
Other assets		(1)		(21)
Accounts payable and accrued liabilities		(697)		322
Accrued payroll and employee benefits		118		104
Income taxes payable		35		10
Other long-term liabilities		4		(4)
otal cash flows provided by operating activities of continuing operations		134		627
Cash flows from investing activities of continuing operations:				
Expenditures for property, plant and equipment		(43)		(48)
Acquisitions of businesses, net of cash acquired of \$9 million and \$5 million in fiscal 2013 and 2012, respectively		(478)		(216)
Net receipts (payments) for purchase price adjustments related to prior year acquisitions		1		(4)
Proceeds from sale of assets		3		84
Other		_		(1)
otal cash flows used in investing activities of continuing operations		(517)		(185)
Cash flows from financing activities of continuing operations:		` '		` ,
Payments on notes payable and long-term debt		(553)		(3)
Sales of stock and exercises of stock options		<b>` 15</b>		21
Repurchases of stock		(21)		(470)
Dividend payments		(124)		
Other		` _'		(2)
otal cash flows used in financing activities of continuing operations		(683)		(454)
Decrease in cash and cash equivalents from continuing operations	ľ	1,066)		(12)
Cash flows from discontinued operations:		1,000)		(12)
Cash provided by (used in) operating activities of discontinued operations		5		(61)
Cash provided by investing activities of discontinued operations		_		168
ncrease in cash and cash equivalents from discontinued operations		5		107
				107
Effect of foreign currency exchange rate changes on cash and cash equivalents				
otal increase (decrease) in cash and cash equivalents		1,061)		96
Cash and cash equivalents at beginning of period		1,592		1,367
Cash and cash equivalents at end of period	\$	531	\$1	1,463

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

		onths Ended ober 31		ths Ended ber 31
	2012	2011	2012	2011
		•	illions)	
Revenues	\$2,870	\$2,790	\$8,462	\$8,026
Costs and expenses:				
Cost of revenues	2,509	2,477	7,429	7,051
Selling, general and administrative expenses	157	333	429	562
Separation transaction expenses	11	_	15	_
Operating income (loss)	193	(20)	589	413
Non-operating income (expense):				
Interest income	2	2	6	3
Interest expense	(20)	(30)	(73)	(90)
Other income (expense), net	2	(2)	8	3
Income (loss) from continuing operations before income taxes	177	(50)	530	329
Provision for income taxes	(65)	(44)	(193)	(186)
Income (loss) from continuing operations	112	(94)	337	143
Discontinued operations (Note 1):				
Income from discontinued operations before income taxes	<u> </u>	4	3	127
Provision for income taxes	<u> </u>	(1)	(1)	(53)
Income from discontinued operations	_	3	2	74
Net income (loss)	\$ 112	\$ (91)	\$ 339	\$ 217

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

			nths Ended ber 31
2012	2011	2012	2011
		,	
\$ 112	\$ (91)	\$ 339	\$ 217
_	_	(1)	7
_	_	1	(3)
_	_	_	4
_	1	_	1
_	(1)		(1)
_	_	_	_
_	_	16	
_	_	(6)	
_	_	10	_
_	_	10	4
\$ 112	\$ (91)	\$ 349	\$ 221
	\$ 112 \$ 112 ———————————————————————————————————	\$ 112 \$ (91)	October 31         Octo           2012         2011         2012           (in millions)         \$ 339           -         -         (1)           -         -         1           -         -         1           -         -         -           -         (1)         -           -         (1)         -           -         -         16           -         -         (6)           -         -         10           -         -         10

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

		tober 31, 2012	12	
		(in mi	lions)	
ASSETS				
Current assets:	_		_	
Cash and cash equivalents	\$	331	\$	1,592
Receivables, net		1,943		2,164
Inventory, prepaid expenses and other current assets		554		439
Assets of discontinued operations		34		36
Total current assets		2,862		4,231
Property, plant and equipment (less accumulated depreciation and amortization of \$447 million and \$424 million at				
October 31, 2012 and January 31, 2012, respectively)		319		348
Intangible assets, net		214		176
Goodwill		2,195		1,800
Deferred income taxes				37
Other assets		76		75
Note receivable from SAIC, Inc. (Note 7)		155		
LARWITE AND STOCKULOURE ROLLIEV	\$	5,821	\$	6,667
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:		4 004		1 001
Accounts payable and accrued liabilities	\$	1,291	\$	1,961
Accrued payroll and employee benefits		624		504
Income taxes payable		41		
Notes payable and long-term debt, current portion		2		553
Liabilities of discontinued operations		8		7
Total current liabilities		1,966		3,025
Notes payable and long-term debt, net of current portion		1,297		1,299
Note payable to SAIC, Inc. (Note 7)		_		120
Other long-term liabilities		148		162
Commitments and contingencies (Notes 10 and 11)				
Stockholder's equity:				
Common stock, \$.01 par value, 10,000 shares authorized, 5,000 shares issued and outstanding at October 31,				
2012 and January 31, 2012		_		_
Additional paid-in capital		233		233
Retained earnings		2,178		1,839
Accumulated other comprehensive loss		(1)		(11)
Total stockholders' equity		2,410		2,061
	\$	5,821	\$	6,667

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY (UNAUDITED)

	Shares of common	ditional paid-in	Retained	umulated other ehensive	
	stock	capital	earnings	 loss	Total
		(in millio	ons, except for sh		
Balance at January 31, 2012	5,000	\$ 233	\$1,839	\$ (11)	\$2,061
Net income	_	_	339		339
Other comprehensive income, net of tax	_	_	_	10	10
Balance at October 31, 2012	5,000	\$ 233	\$2,178	\$ (1)	\$2,410

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Nine Months End October 31			ed
		2012		2011
Cash flows from apprating activities of continuing apprations:		(in mi	llions)	
Cash flows from operating activities of continuing operations:  Net income	\$	339	\$	217
Income from discontinued operations	φ	(2)	Ψ	(74)
Adjustments to reconcile net income to net cash provided by operating activities of continuing operations:		(2)		(14)
Depreciation and amortization		85		86
Stock-based compensation		67		64
Impairment losses		2		19
Net gain on sales and disposals of assets		(7)		(32)
Other		3		(02)
Increase (decrease) in cash and cash equivalents, net of acquisitions and divestitures, resulting from changes		•		
in:				
Receivables		271		(94)
Inventory, prepaid expenses and other current assets		(79)		38
Deferred income taxes		(4)		(11)
Other assets		(1)		(21)
Accounts payable and accrued liabilities		( <del>-)</del> (697)		322
Accrued payroll and employee benefits		118		104
Income taxes payable		35		10
Other long-term liabilities		4		(4)
Total cash flows provided by operating activities of continuing operations		134		624
Cash flows from investing activities of continuing operations:				
Expenditures for property, plant and equipment		(43)		(48)
Acquisitions of businesses, net of cash acquired of \$9 million and \$5 million in fiscal 2013 and 2012, respectively		(478)		(216)
Net receipts (payments) for purchase price adjustments related to prior year acquisitions		1		(4)
Proceeds from sale of assets		3		84
Other		_		(1)
Total cash flows used in investing activities of continuing operations		(517)		(185)
Cash flows from financing activities of continuing operations:				
Proceeds from note payable to SAIC, Inc.		40		601
Payments on note payable to SAIC, Inc.		(369)	(1	1,047)
Payments on notes payable and long-term debt		(553)		(3)
Dividend payments		(1)		_
Other				(2)
Total cash flows used in financing activities of continuing operations		(883)		(451)
Decrease in cash and cash equivalents from continuing operations	(:	1,266)		(12)
Cash flows from discontinued operations:				
Cash provided by (used in) operating activities of discontinued operations		5		(61)
Cash provided by investing activities of discontinued operations				168
Increase in cash and cash equivalents from discontinued operations		5		107
Effect of foreign currency exchange rate changes on cash and cash equivalents				1
Total increase (decrease) in cash and cash equivalents		1,261)		96
Cash and cash equivalents at beginning of period		1,592		1,367
Cash and cash equivalents at end of period	\$	331	\$ 1	L,463

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

### Note 1—Summary of Significant Accounting Policies:

### Nature of Operations and Basis of Presentation

SAIC, Inc. ("SAIC") is a holding company whose direct 100%-owned subsidiary is Science Applications International Corporation ("Science Applications"), a provider of scientific, engineering, systems integration and technical services and solutions in the areas of defense, health, energy, infrastructure, intelligence, surveillance, reconnaissance and cybersecurity to agencies of the U.S. Department of Defense (DoD), the intelligence community, the U.S. Department of Homeland Security, and other U.S. Government civil agencies, state and local government agencies, foreign governments and customers in select commercial markets.

The condensed consolidated financial statements of SAIC include the accounts of its majority-owned and 100%-owned subsidiaries, including Science Applications. The condensed consolidated financial statements of Science Applications include the accounts of its majority-owned and 100%-owned subsidiaries. SAIC does not have separate operations, assets or liabilities independent of Science Applications, except for a note with Science Applications (the "related party note"), on which interest is recognized. From time to time, SAIC issues stock to employees of Science Applications and its subsidiaries, which is reflected in SAIC's Condensed Consolidated Statement of Stockholders' Equity and results in an increase to the related party note (see Note 7). All intercompany transactions and accounts have been eliminated in consolidation.

These Combined Notes to Condensed Consolidated Financial Statements apply to both SAIC and Science Applications. As SAIC consolidates Science Applications for financial statement purposes, disclosures that relate to activities of Science Applications also apply to SAIC. References to the "Company" refer collectively to SAIC, Science Applications, and its consolidated subsidiaries unless otherwise noted.

The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and combined notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2012. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Estimates have been prepared by management on the basis of the most current and best available information at the time of estimation and actual results could differ from those estimates.

In the opinion of management, the financial information as of October 31, 2012 and for the three and nine months ended October 31, 2012 and 2011 reflects all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation thereof. Operating results for the three and nine months ended October 31, 2012 are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2013, or any future period.

Unless otherwise noted, references to years are for fiscal years ended January 31. For example, the fiscal year ending January 31, 2013 is referred to as "fiscal 2013" in these combined notes to condensed consolidated financial statements.

### **Planned Separation transaction**

In August 2012, the Company announced that its board of directors authorized management to pursue a plan to separate into two independent, publicly traded companies. The proposed separation transaction is intended to take the form of a tax-free spin-off to SAIC stockholders of 100% of the shares of a newly formed company focused on government technical and enterprise information technology services. The separation is expected to occur in the latter half of calendar year 2013, subject to final approval of the board of directors and certain customary conditions, including a ruling from the Internal Revenue Service (IRS) as to the tax-free nature of the transaction. Although the Company expects that the separation of its businesses will be consummated, there can be no assurance that a separation will ultimately occur. Upon completion of the separation transaction, the operating results of the separated business will be included in discontinued operations.

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

During the three and nine months ended October 31, 2012, separation transaction expenses were as follows:

	Three Months Ended October 31, 2012			
	(in mill	(in millions)		
Strategic advisory services	\$ 7	\$	11	
Investment banking services	3		3	
Legal and accounting services	1		1	
Separation transaction expenses in operating income	11		15	
Less: income tax benefit	(4)		(6)	
Separation transaction expenses, net of tax	\$ 7	\$	9	

Consistent with the Company's policy for acquisitions, the Company has recognized a tax benefit for the separation transaction expenses. Certain of the separation transaction expenses will be capitalized for tax purposes if the separation transaction is completed, resulting in a reversal of tax benefits previously recognized.

### Receivables

The Company's accounts receivable include unbilled receivables, which consist of costs and fees billable upon contract completion or the occurrence of a specified event, the majority of which is expected to be billed and collected within one year. Unbilled receivables are stated at estimated realizable value. Since the Company's receivables are primarily with the U.S. Government, the Company does not have a material credit risk exposure. Contract retentions are billed when the Company has negotiated final indirect rates with the U.S. Government and, once billed, are subject to audit and approval by government representatives. Consequently, the timing of collection of retention balances is outside the Company's control. Based on the Company's historical experience, the majority of retention balances are expected to be collected beyond one year. The Company has extended deferred payment terms with contractual maturities that may exceed one year to three commercial customers related to certain construction projects. As of October 31, 2012, the Company had outstanding receivables from these customers with deferred payment terms of \$81 million, which are expected to be collected in calendar 2013 and 2014, when the customers have obtained financing. When events or conditions indicate that amounts outstanding from customers may become uncollectible, an allowance is estimated and recorded.

### **Changes in Estimates on Contracts**

Changes in estimates related to certain types of contracts accounted for using the percentage of completion method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes. Changes in these estimates can routinely occur over the contract performance period for a variety of reasons, including changes in contract scope, changes in contract cost estimates due to unanticipated cost growth or retirements of risk for amounts different than estimated, and changes in estimated incentive or award fees. Aggregate changes in contract estimates increased operating income by \$8 million (\$0.01 per diluted share) and \$9 million (\$0.01 per diluted share) for the three and nine months ended October 31, 2012, respectively. Aggregate changes in contract estimates increased operating income by \$6 million (\$0.01 per diluted share) and \$33 million (\$0.06 per diluted share) for the three and nine months ended October 31, 2011, respectively.

### **Discontinued Operations**

From time-to-time, the Company may dispose (or management may commit to plans to dispose) of non-strategic components of the business, which are reclassified as discontinued operations for all periods presented.

In November 2012, the Company sold certain components of its business, which were historically included in the Company's Health, Energy and Civil Solutions segment, primarily focused on providing operational test and evaluation services.

In fiscal 2012, the Company sold certain components of its business, which were historically included in the Company's Health, Energy and Civil Solutions segment, primarily focused on providing information technology services to international oil and gas companies. The Company received net proceeds of \$167 million resulting in a gain on sale before income taxes of \$111 million related to this sale. Under the terms of the definitive agreement, the Company has retained the assets and obligations of its defined benefit pension plan in the United Kingdom. The Company has classified the operating results of these business components, including pension expense through the date of sale, as discontinued operations for all periods presented. Following the sale, as a result of retaining the pension obligation, the remaining components of ongoing pension expense, primarily interest costs and assumed return on plan assets, are recorded in continuing operations.

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The pre-sale operating results of these discontinued operations were as follows:

		Months Ended October 31	d
	2012	201	11
	(iı	n millions)	
Revenues	\$ 55	\$ 1	140
Costs and expenses:			
Cost of revenues	48	1	114
Selling, general and administrative expenses	3		12
Operating income	\$ 4	\$	14

Income from discontinued operations also includes other activity that is immaterial and not reflected in the table above.

### Pension

During the fiscal quarter ended April 30, 2012, the Company transferred \$46 million of pension plan assets to a successor contractor's plan on behalf of certain participants in the Company's defined benefit pension plan who previously transferred their employment to the successor contractor and settled \$63 million of related pension plan obligations. As a result of the transfer, the Company recorded an immaterial settlement gain in selling, general and administrative expenses during the first quarter of fiscal 2013.

### Supplementary Cash Flow Information

Supplementary cash flow information, including non-cash investing and financing activities, for the periods presented was as follows:

	Nine Months Er October 31			ded
	20	012	2	2011
		(in mi	llions)	
Stock exchanged at fair value upon exercises of stock options	\$	_	\$	14
Vested stock issued as settlement of annual bonus accruals	\$	2	\$	3
Decrease in accrued stock repurchases	\$	_	\$	(7)
Stock issued in lieu of cash dividend	\$	2	\$	
Fair value of assets acquired in acquisitions	\$	541	\$	239
Less: cash paid in acquisitions, net of cash acquired of \$9 million and \$5 million in fiscal 2013 and 2012, respectively	(	478)		(216)
Liabilities assumed in acquisitions, including accrued acquisition payments	\$	63	\$	23
Cash paid for interest (including discontinued operations)	\$	53	\$	53
Cash paid for income taxes (including discontinued operations)	\$	126	\$	194

### **Income Tax Rate**

The Company's effective tax rate for the three and nine months ended October 31, 2011 significantly exceeded statutory tax rates primarily due to the estimated non-deductible portion of the CityTime payment (see Notes 10 and 11). Subsequent to October 31, 2012, the Company entered into an issue resolution agreement with the IRS with respect to the tax deductible portion of the CityTime payment. The resolution of this tax matter will result in a \$102 million reduction in the Company's uncertain tax positions and a \$96 million reduction in income tax expense during the fourth quarter of fiscal year 2013.

### Accounting Standards Updates Issued But Not Yet Adopted

Accounting standards and updates issued but not effective for the Company until after October 31, 2012 are not expected to have a material effect on the Company's consolidated financial position or results of operations.

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

### Note 2—Earnings Per Share (EPS):

The Company is required to allocate a portion of its earnings to its unvested stock awards containing nonforfeitable rights to dividends or dividend equivalents (participating securities) in calculating EPS using the two-class method.

Unvested stock awards granted prior to fiscal 2013 are participating securities requiring application of the two-class method. In fiscal 2013, the Company began issuing unvested stock awards that have forfeitable rights to dividends or dividend equivalents. These stock awards are not participating securities requiring application of the two-class method but are dilutive common share equivalents subject to the treasury stock method. Basic EPS is computed by dividing income less earnings allocable to participating securities by the basic weighted average number of shares outstanding. Diluted EPS is computed similar to basic EPS, except the weighted average number of shares outstanding is increased to include the dilutive effect of outstanding stock options and other stock-based awards.

A reconciliation of the income used to compute basic and diluted EPS for the periods presented was as follows:

	Three Months Ended October 31				Nine Months Ended October 31		
		2012		2011	2012		2011
				(in mi	llions)		
Basic EPS:							
Income from continuing operations, as reported	\$	112	\$	(92)	\$ 337	\$	146
Less: allocation of distributed and undistributed earnings to participating securities		(2)		_	(7)		(5)
Income (loss) from continuing operations, for computing basic EPS	\$	110	\$	(92)	\$ 330	\$	141
Net income (loss), as reported	\$	112	\$	(89)	\$ 339	\$	220
Less: allocation of distributed and undistributed earnings to participating securities		(2)		_	(7)		(8)
Net income (loss), for computing basic EPS	\$	110	\$	(89)	\$ 332	\$	212
Diluted EPS:							
Income (loss) from continuing operations, as reported	\$	112	\$	(92)	\$ 337	\$	146
Less: allocation of distributed and undistributed earnings to participating securities		(2)		_	(7)		(5)
Income (loss) from continuing operations, for computing diluted EPS	\$	110	\$	(92)	\$ 330	\$	141
Net income, as reported	\$	112	\$	(89)	\$ 339	\$	220
Less: allocation of distributed and undistributed earnings to participating securities		(2)		_	(7)		(8)
Net income (loss), for computing diluted EPS	\$	110	\$	(89)	\$ 332	\$	212

A reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented was as follows:

	Three Month Octobe			Nine Months Ended October 31		
	2012	2011	2012	2011		
		(in millio	ons)			
Basic weighted average number of shares outstanding	334	329	333	338		
Dilutive common share equivalents—stock options and other stock awards	_	_	_	1		
Diluted weighted average number of shares outstanding	334	329	333	339		

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Basic and diluted EPS for the periods presented was as follows:

		nths Ended ber 31		Nine Months Ended October 31	
	2012	2011	2012	2011	
Basic:					
Income (loss) from continuing operations	\$ .33	\$ (.28)	\$ .99	\$ .42	
Income from discontinued operations	<del>_</del>	.01	.01	.21	
	\$ .33	\$ (.27)	\$ 1.00	\$ .63	
Diluted:					
Income (loss) from continuing operations	\$ .33	\$ (.28)	\$ .99	\$ .42	
Income from discontinued operations	<del>_</del>	.01	.01	.21	
	\$ .33	\$ (.27)	\$ 1.00	\$ .63	

The following stock-based awards were excluded from the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented:

	Three Montl Octobe			Nine Months Ended October 31	
	2012	2011	2012	2011	
	(in millions)				
Antidilutive stock options excluded	20	21	20	21	
Performance-based stock awards excluded	1	1	1	1	

### Note 3—Stock-Based Compensation:

Total Stock-Based Compensation. Total stock-based compensation expense for the periods presented was as follows:

	Three Months Ended October 31				Nine Months Ended October 31		
	 2012	2	011	2012		2011	
	(in millions)						
Stock options	\$ 2	\$	3	\$ 9	\$	13	
Vesting stock awards	17		19	54		54	
Performance-based stock awards	2		(1)	4		(3)	
Total stock-based compensation expense	\$ 21	\$	21	\$ 67	\$	64	

Stock Options. Stock options granted during the nine months ended October 31, 2012 and 2011 have terms of seven years and a vesting period of four years, except for stock options granted to the Company's outside directors, which have a vesting period of one year.

The fair value of the Company's stock option awards is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted average grant-date fair value and assumptions used to determine the fair value of stock options granted for the periods presented were as follows:

	Nine Monti Octob	
	2012	2011
Weighted average grant-date fair value	\$1.81	\$4.21
Expected term (in years)	5.0	4.9
Expected volatility	24.5%	23.4%
Risk-free interest rate	1.0%	2.2%
Dividend yield	3.7%	0%

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Stock option activity for the nine months ended October 31, 2012 was as follows:

			Weighted	
	Shares of		average	
	stock under	Weighted	remaining	
	stock	average	contractual	Aggregate
	options	exercise price	term	intrinsic value
	(in millions)		(in years)	(in millions)
Outstanding at January 31, 2012	20.8	\$ 17.90	2.5	\$ —
Options granted	5.0	13.20		
Options forfeited or expired	(5.7)	17.48		
Outstanding at October 31, 2012	20.1	16.85	3.2	_
Exercisable at October 31, 2012	9.3	18.33	1.4	_

Vesting Stock Awards. In fiscal 2013, the Company began granting restricted stock units that have forfeitable dividend rights and no voting rights until the units vest and become included in shares of common stock outstanding. Prior to January 31, 2012, the Company granted restricted stock awards that have non-forfeitable dividend rights and voting rights and are included in shares outstanding upon issuance (prior to vesting). Vesting stock award activity for the nine months ended October 31, 2012 was as follows:

01-----

	Snares of stock		weigntea	
	under stock			
	awards	dat	e fair value	
	(in millions)			
Unvested stock awards at January 31, 2012	12.0	\$	17.50	
Awards granted	6.5		13.18	
Awards forfeited	(1.0)		15.83	
Awards vested	(4.7)		17.86	
Unvested stock awards at October 31, 2012	12.8		15.30	

The fair value of vesting stock awards that vested during the nine months ended October 31, 2012 and 2011 was \$64 million and \$66 million, respectively.

Performance-Based Stock Awards. The Company's performance-based stock awards vest and the stock is issued at the end of a three-year period based upon the achievement of specific performance criteria, with the number of shares ultimately awarded ranging from zero to 150% of the specified target awards. For awards granted in fiscal 2013, one-third of the target number of shares of stock granted under the awards will be allocated to each fiscal year over the three-year performance period and the actual number of shares to be issued with respect to each fiscal year will be based upon the achievement of that fiscal year's performance criteria. For performance-based stock awards granted prior to fiscal 2013, the number of shares of stock to be issued under the awards is determined based upon the achievement of the performance criteria measured over the entire three-year performance period. Performance-based stock award activity for the nine months ended October 31, 2012 was as follows:

	Expected number of shares of stock		
	to be issued under		
	performance-		Weighted
	based stock	ave	rage grant-
	awards	date	e fair value
	(in millions)		
Outstanding at January 31, 2012	0.5	\$	17.02
Awards granted	0.8		13.14
Outstanding at October 31, 2012	1.3		14.15

Adjustments to the expected number of shares of stock to be issued may occur due to changes in the expected level of achievement of the performance goals over the life of the awards.

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

### Note 4—Acquisitions:

maxIT Healthcare Holdings, Inc. In August 2012, the Company acquired 100% of the stock of maxIT Healthcare Holdings, Inc., a provider of clinical, business and information technology services primarily to commercial hospital groups and other medical delivery organizations, for a preliminary purchase price of \$473 million paid in cash plus a \$14 million cash payment for excess working capital delivered at closing, subject to adjustment. The Company will make an additional payment of up to \$20 million after receipt of certain tax refunds. This acquisition expands the Company's commercial consulting practice in electronic health record (EHR) implementation and optimization and strengthens the Company's capabilities to provide these services to its federal healthcare customers as those customers migrate to commercial off-the-shelf EHR applications. The preliminary purchase price allocation resulted in goodwill of \$395 million (none of which is tax deductible) and identifiable finite-lived intangible assets of \$72 million (amortizable over a weighted average life of four years). This acquisition was in the Health, Energy and Civil Solutions segment.

The preliminary estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for this acquisition was as follows (in millions):

Cash	\$	9
Receivables		50
Other assets		24
Accounts payable, accrued liabilities and accrued payroll and employee benefits	(	(20)
Deferred tax liabilities, net	(	(26)
Total identifiable net assets acquired		37
Goodwill	3	395
Intangible assets		72
Total preliminary purchase price (including accrued acquisition payments of \$17 million)	\$5	504

Since the date of acquisition of maxIT Healthcare Holdings, Inc. through October 31, 2012, the Company has recognized revenues of \$68 million related to this acquisition.

### Note 5—Goodwill and Intangible Assets:

The changes in the carrying value of goodwill for Defense Solutions (DS), Health, Energy and Civil Solutions (HECS) and Intelligence and Cybersecurity Solutions (ICS) were as follows:

	DS	HECS	ICS	Total
		(in mi	llions)	
Goodwill at January 31, 2012	\$410	\$ 759	\$631	\$1,800
Corporate reorganizations	_	(10)	10	
Acquisition of a business	_	395	_	395
Goodwill at October 31, 2012	\$410	\$1,144	\$641	\$2,195

Corporate reorganizations in fiscal 2013 resulted from transfers of certain operations between the Company's reportable segments. Additionally, prior year amounts have been adjusted for discontinued operations.

Intangible assets consisted of the following:

		October 31, 2012				January 31, 2012		
	Gross			Net	Gross			Net
	carrying value		umulated ortization	carrying value	carrying value		umulated ortization	carrying value
			71111111111	(in mill		- Carrie	51 ti. Edito!!	raido
Finite-lived intangible assets:								
Customer relationships	<b>\$ 177</b>	\$	(66)	\$ 111	\$ 120	\$	(62)	\$ 58
Software and technology	145		(60)	85	148		(48)	100
Other	2		(1)	1	2		(1)	1
Total finite-lived intangible assets	324		(127)	197	270		(111)	159
Indefinite-lived intangible assets:							, ,	
In-process research and development	13			13	13			13
Trade names	4		_	4	4		_	4
Total indefinite-lived intangible assets	17		_	17	17		_	17
Total intangible assets	\$ 341	\$	(127)	\$ 214	\$ 287	\$	(111)	\$ 176

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Finite-lived intangible assets with a gross carrying value of \$16 million became fully amortized during the nine months ended October 31, 2012 and are no longer reflected in the gross carrying value. Amortization expense related to amortizable intangible assets was \$13 million and \$32 million for the three and nine months ended October 31, 2012, respectively, and \$13 million and \$35 million for the three and nine months ended October 31, 2011, respectively.

During the three and nine months ended October 31, 2012, the Company recognized impairment losses for intangible assets of \$1 million and \$2 million, respectively. During the three and nine months ended October 31, 2011, the Company recognized an impairment loss on intangible assets of \$19 million. There were no goodwill impairment losses during the three and nine months ended October 31, 2012 and 2011.

The estimated annual amortization expense related to finite-lived intangible assets as of October 31, 2012 was as follows:

Fiscal Year Ending January 31	(in million
2013 (remainder of the fiscal year)	\$ 1
2014	
2015	;
2016	;
2017	
2018	-
2019 and thereafter	· · · · · · · · · · · · · · · · · · ·
	<b>ታ</b> 10

Actual amortization expense in future periods could differ from these estimates as a result of future acquisitions, divestitures, impairments, the outcome and timing of completion of in-process research and development projects (the assets of which will become amortizable upon completion and placement into service, or will be impaired if abandoned), adjustments to preliminary valuations of intangible assets and other factors.

#### Note 6—Financial Instruments:

In addition to cash held in insured bank deposits, the Company's cash equivalents were primarily comprised of investments in several large institutional money market funds that invest primarily in bills, notes and bonds issued by the U.S. Treasury, U.S. Government guaranteed repurchase agreements fully collateralized by U.S. Treasury obligations, U.S. Government guaranteed securities and investment-grade corporate securities that have original maturities of three months or less. There are no restrictions on the withdrawal of the Company's cash and cash equivalents. The Company's cash equivalents are recorded at historical cost which equals fair value based on quoted market prices (Level 1 input as defined by the accounting standard for fair value measurements).

SAIC has a revolving credit facility, which is fully and unconditionally guaranteed by Science Applications, providing for up to \$750 million in unsecured borrowing capacity at interest rates determined, at SAIC's option, based on either LIBOR plus a margin or a defined base rate through fiscal 2017. During the first quarter of fiscal 2013, the Company extended the maturity date of the revolving credit facility for one additional year, to March 2016, as provided for in the terms of the revolving credit facility. As of October 31, 2012 and January 31, 2012, there were no borrowings outstanding under the revolving credit facility.

The revolving credit facility contains certain customary representations and warranties, as well as certain affirmative and negative covenants. The financial covenants contained in the revolving credit facility require that, for a period of four trailing fiscal quarters, the Company maintains a ratio of consolidated funded debt, including borrowings under this facility, to earnings before interest, taxes, depreciation and amortization (EBITDA) adjusted for other items as defined in the credit facility of not more than 3.0 to 1.0 and a ratio of EBITDA adjusted for other items as defined in the credit facility to interest expense of greater than 3.5 to 1.0. The Company was in compliance with these financial covenants as of October 31, 2012. A failure by the Company to meet these financial covenants in the future would reduce and could eliminate the Company's borrowing capacity under the revolving credit facility.

Other covenants restrict certain of the Company's activities, including among other things, its ability to create liens, dispose of certain assets and merge or consolidate with other entities. The revolving credit facility also contains certain customary events of default, including, among others, defaults based on certain bankruptcy and insolvency events, nonpayment, cross-defaults to other debt, breach of specified covenants, Employee Retirement Income Security Act (ERISA) events, material monetary judgments, change of control events and the material inaccuracy of the Company's representations and warranties.

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The Company's notes payable and long-term debt consisted of the following:

		Effective				
	Stated	interest O		October 31,		nuary 31,
	interest rate	rate		2012		2012
		(dollars in m	nillions)			
SAIC senior unsecured notes:						
\$450 million notes issued in fiscal 2011, which mature in December 2020	4.45%	4.53%	\$	449	\$	449
\$300 million notes issued in fiscal 2011, which mature in December 2040	5.95%	6.03%		300		300
Science Applications senior unsecured notes:						
\$550 million notes issued in fiscal 2003, which matured in July 2012	6.25%	6.50%				550
\$250 million notes issued in fiscal 2003, which mature in July 2032	7.13%	7.43%		248		248
\$300 million notes issued in fiscal 2004, which mature in July 2033	5.50%	5.78%		296		296
Capital leases and other notes payable due on various dates through fiscal						
2018	0-2.5%	Various		6		9
Total notes payable and long-term debt				1,299		1,852
Less current portion				2		553
Total notes payable and long-term debt, net of current portion			\$	1,297	\$	1,299
Fair value of notes payable and long-term debt			\$	1,449	\$	2,011

The Company paid \$550 million to settle the 6.25% notes at maturity in July 2012.

The fair value of long-term debt is determined based on current interest rates available for debt with terms and maturities similar to the Company's existing debt arrangements (Level 2 and 3 inputs as defined by the accounting standard for fair value measurements).

The senior unsecured notes contain customary restrictive covenants, including, among other things, restrictions on the Company's ability to create liens and enter into sale and leaseback transactions. The Company was in compliance with all covenants as of October 31, 2012.

### **Note 7—Related Party Transactions:**

Science Applications has fully and unconditionally guaranteed the obligations of SAIC under its \$450 million 4.45% notes and \$300 million 5.95% notes. These notes have been reflected as debt of Science Applications in these condensed consolidated financial statements. Science Applications has fully and unconditionally guaranteed any borrowings under SAIC's amended and restated revolving credit facility maturing in fiscal 2017. SAIC has fully and unconditionally guaranteed the obligations of Science Applications under its \$300 million 5.5% notes and \$250 million 7.13% notes.

SAIC and Science Applications have a related party note in connection with a loan of cash between the entities, issuances of stock by SAIC to employees of Science Applications and its subsidiaries and Science Applications' payment of certain obligations on behalf of SAIC. The related party note bears interest based on LIBOR plus a market-based premium. Portions of the related party note may be repaid at any time prior to its maturity date in November 2013. This maturity date will be automatically extended for successive one-year periods unless either SAIC or Science Applications provides prior notice to the other party.

### Note 8—Accumulated Other Comprehensive Loss:

The components of accumulated other comprehensive loss were as follows:

	Octo	per 31, 2012	Janu	uary 31, 2012
		(in mil	lions)	
Foreign currency translation adjustments, net of taxes of \$(1) million and \$(2) million as of October 31, 2012 and January 31, 2012, respectively	\$	2	\$	2
Unrecognized net loss on settled derivative instruments associated with outstanding debt, net of taxes of \$3 million as of October 31, 2012 and January 31, 2012		(5)		(5)
Unrecognized net loss on defined benefit plan, net of taxes of (\$1) million and \$5 million, as of October 31, 2012 and January 31, 2012, respectively		2		(8)
Total accumulated other comprehensive loss, net of taxes of \$1 million and \$6 million as of October 31, 2012 and January 31, 2012, respectively	\$	(1)	\$	(11)

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

As of October 31, 2012, there is less than \$1 million of the unrealized net loss on settled derivative instruments (pre-tax) that will be amortized and recognized as interest expense during the next 12 months.

### Note 9—Business Segment Information:

The Company defines its reportable segments based on the way the chief operating decision maker (CODM), currently its chief executive officer, manages the operations of the Company for purposes of allocating resources and assessing performance.

The segment information for the periods presented was as follows:

		onths Ended		ths Ended
		ober 31	Octob	
	2012		2012	2011
		(in mi	illions)	
Revenues:				
Defense Solutions	\$1,183	\$1,117	\$3,597	\$3,339
Health, Energy and Civil Solutions	743	726	2,077	1,997
Intelligence and Cybersecurity Solutions	945	947	2,792	2,691
Corporate and Other		1	_	2
Intersegment elimination	(1	(1)	(4)	(3)
Total revenues	\$2,870	\$2,790	\$8,462	\$8,026
Operating income (loss):				
Defense Solutions	\$ 91	\$ (133)	\$ 284	\$ 45
Health, Energy and Civil Solutions	69	77	168	187
Intelligence and Cybersecurity Solutions	68	54	203	215
Corporate and Other	(35	(18)	(66)	(34)
Total operating income (loss)	\$ 193	\$ (20)	\$ 589	\$ 413

Prior to February 1, 2012, the Intelligence and Cybersecurity Solutions reportable segment represented the aggregation of the Cyber and Information Solutions business unit and the Intelligence, Surveillance and Reconnaissance group. Effective February 1, 2012, the Cyber and Information Solutions business unit, which previously reported directly to the CODM, commenced reporting to the Intelligence, Surveillance and Reconnaissance group. After this change the reportable segment name has remained Intelligence and Cybersecurity Solutions. Also effective February 1, 2012, certain operations were transferred between the Company's reportable segments. Prior year amounts have been adjusted for consistency with the current year's presentation.

# Note 10—Legal Proceedings:

### **Timekeeping Contract with City of New York**

In March 2012, the Company reached a settlement with the U.S. Attorney's Office for the Southern District of New York and the City of New York (City) relating to investigations being conducted by the U.S. Attorney's Office and the City with respect to the Company's contract to develop and implement an automated time and attendance and workforce management system (CityTime) for certain agencies of the City. As part of this settlement, the Company entered into a deferred prosecution agreement with the U.S. Attorney's Office, under which the Company paid approximately \$500 million and the U.S. Attorney's Office deferred prosecution of a single criminal count against the Company, which alleged that the Company, through the conduct of certain managerial employees and others, caused the City to significantly overpay for the CityTime system. If the Company complies with the terms of the deferred prosecution agreement, the U.S. Attorney will dismiss the criminal count at the end of a three-year period. In August 2012, the Company entered into an administrative agreement with the U.S. Army, on behalf of all agencies of the U.S. Government that confirms the Company's continuing eligibility to enter into and perform contracts with all agencies of the U.S. Government following the CityTime settlement. The Army has determined that the U.S. Government will have adequate assurances under the terms of the administrative agreement will have adequate assurances under the terms of the administrative agreement, the Company has agreed, among other things, to maintain a contractor responsibility program having the specific elements described in the administrative agreement, including retaining a monitor and providing certain reports to the U.S. Army. The administrative agreement will continue in effect for five years, provided that the Company may request earlier termination after three years.

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

### **Data Privacy Litigation**

The Company is a defendant in a putative class action, In Re: Science Applications International Corporation (SAIC) Backup Tape Data Theft Litigation, a Multidistrict Litigation (MDL), in the U.S. District Court for the District of Columbia. The MDL action consolidates for pretrial proceedings the following seven individual putative class action lawsuits filed against the Company from October 2011 through March 2012: (1) Richardson, et al. v. TRICARE Management Activity, Science Applications International Corporation, United States Department of Defense, et al. in U.S. District Court for the District of Columbia; (2) Arellano, et al. v. SAIC, Inc. in U.S. District Court for the Western District of Texas; (3) Biggerman, et al. v. TRICARE Management Activity, Science Applications International Corporation, United States Department of Defense, et al. in U.S. District Court for the District of Columbia; (4) Moskowitz, et al. v. TRICARE Management Activity, Science Applications International Corporation, United States Department of Defense, et al. in U.S. District Court for the District of Columbia; (5) Palmer, et al. v. TRICARE Management Activity, Science Applications International Corporation, United States Department of Defense, et al., in U.S. District Court for the District of Columbia; (6) Losack, et al. v. SAIC, Inc. in U.S. District Court for the Southern District of California; and (7) Deatrick v. Science Applications International Corporation in U.S. District Court for the Northern District of California. The lawsuits were filed following the theft of computer backup tapes from a vehicle of a Company employee. The employee was transporting the backup tapes between federal facilities under an IT services contract the Company was performing in support of TRICARE, the health care program for members of the military, retirees and their families. The tapes contained personally identifiable and protected health information of approximately five million military clinic and hospital patients. There is no evidence that any of the data on the backup tapes has actually been accessed or viewed by an unauthorized person. In order for an unauthorized person to access or view the data on the backup tapes, it would require knowledge of and access to specific hardware and software and knowledge of the system and data structure. The Company has notified potentially impacted persons by letter and has offered one year of credit monitoring services to those who request these services and in certain circumstances, one year of identity restoration services.

In October 2012, plaintiffs filed a consolidated amended complaint in the MDL action, which supersedes all previously filed complaints in the individual lawsuits. The consolidated amended complaint includes allegations of negligence, breach of contract, breach of implied-in-fact contract, invasion of privacy by public disclosure of private facts and statutory violations of the Texas Deceptive Trade Practices Act, the California Confidentiality of Medical Information Act, California data breach notification requirements, the California Unfair Competition Law, various state consumer protection or deceptive practices statutes, state privacy statutes, the Fair Credit Reporting Act and the Privacy Act of 1974. The consolidated amended complaint seeks monetary relief, including unspecified actual damages, punitive damages, statutory damages of \$1,000 for each class member and attorneys' fees, as well as injunctive and declaratory relief.

The Company intends to vigorously defend itself against the claims made in the class action lawsuits. In November 2012, the Company filed a motion to dismiss all claims against the Company alleged in the consolidated amended complaint. The Company has insurance coverage against judgments or settlements relating to the claims being brought in these lawsuits, with a \$10 million deductible. The insurance coverage also covers the Company's defense costs, subject to the same deductible. As of October 31, 2012, the Company has recorded a loss provision of \$10 million related to these lawsuits, representing the low end of the Company's estimated gross loss. The Company believes that, if any loss is experienced by the Company in excess of its estimate, such a loss would not exceed the Company's insurance coverage. As these lawsuits progress, many factors will affect the amount of the ultimate loss resulting from these claims being brought against the Company, including the outcome of any motions to dismiss, the results of any discovery, the outcome of any pretrial motions and the courts' rulings on certain legal issues.

The Company has been informed that the Office for Civil Rights (OCR) of the Department of Health and Human Services (HHS) is investigating matters related to the incident. OCR is the division of HHS charged with enforcement of the Health Insurance Portability and Accountability Act of 1996, as amended (HIPAA) and the privacy, security and data breach rules which implement HIPAA. OCR may, among other things, require a corrective action plan and impose civil monetary penalties against the data owner (Department of Defense) and, in certain situations, against the data owners' contractors, such as the Company. The Company is cooperating with TRICARE in responding to the OCR investigation.

### **Derivative and Securities Litigation**

Between February and April 2012, six stockholder derivative lawsuits were filed, each purportedly on the Company's behalf. One case has been withdrawn; one case, captioned *Martin v. Havenstein et al.*, is pending in New York Supreme Court, New York County; and four cases were consolidated in the U.S. District Court for the Southern District of New York in *In re SAIC, Inc. Derivative Litigation*. Each complaint asserts claims against the Company's directors and against varying groups of the Company's current and former officers, including two former chief executive officers, the chief financial officer, the former manager of the CityTime program, and the former chief systems engineer of the CityTime program. The complaints

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

claim that the defendants breached their fiduciary duties to the Company with respect to the CityTime contract for various reasons, including failure to supervise the adequacy of the Company's internal controls, allowing the Company to issue misleading financial statements, and failure to exercise their oversight responsibilities to ensure that the Company complied with applicable laws, rules and regulations. The consolidated derivative complaint further claims that the defendants are liable to the Company under theories of unjust enrichment, gross mismanagement, abuse of control, and violation of Section 14(a) of the Securities Exchange Act. The *Martin* complaint further claims that the defendants breached their oversight responsibilities related to the TRICARE matter described above. The Company has filed a motion to dismiss each of these complaints because the respective plaintiffs did not serve a pre-suit demand before filing the derivative complaints. The Company has also received two stockholder demand letters related to CityTime (one of which is also related to TRICARE), which an independent committee of the Company's board of directors is currently reviewing.

Between February and April 2012, alleged stockholders filed three putative securities class actions. One case was withdrawn and two cases were consolidated in the U.S. District Court for the Southern District of New York in *In re SAIC, Inc. Securities Litigation*. The consolidated securities complaint names as defendants the Company, its chief financial officer, two former chief executive officers, a former group president, and the former program manager on the CityTime program, and was filed purportedly on behalf of all purchasers of SAIC's common stock from April 11, 2007 through September 1, 2011. The consolidated securities complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on allegations that the Company and individual defendants made misleading statements or omissions about the Company's revenues, operating income, and internal controls in connection with disclosures relating to the CityTime project. The plaintiffs seek to recover from the Company and the individual defendants an unspecified amount of damages class members allegedly incurred by buying SAIC's stock at an inflated price. The Company intends to vigorously defend against these claims and has filed a motion to dismiss the consolidated securities complaint.

The Company currently believes that a loss relating to the above-described stockholder matters is reasonably possible, but the Company cannot reasonably estimate the range of loss in light of the fact that these matters are in their early stages.

### **Greek Government Contract**

Background and Arbitration. In May 2003, the Company entered into a firm-fixed-price contract with the Hellenic Republic of Greece (the Customer) to provide a Command, Control, Communications, Coordination and Integration System (the System) to support the 2004 Athens Summer Olympic Games (the Olympics) and to serve as the security system for the Customer's public order departments following completion of the Olympics.

In November 2008, the Customer accepted the System in writing pursuant to the requirements of the contract. At the time, the Customer determined that the System substantially complied with the terms of the contract and accepted the System with certain alleged minor omissions and deviations. Upon System acceptance, the Company invoiced the Customer for approximately \$18 million, representing the undisputed portion of the contract balance owed to the Company. The Customer has not paid this final invoice.

In June 2009, the Company initiated arbitration before the International Chamber of Commerce against the Customer seeking damages for breaches of contract by the Customer. The Company seeks (i) aggregate damages in excess of \$89 million for payment of amounts owed and other claims and damages, (ii) recovery of advance payment and performance bond amounts totaling \$24 million and (iii) costs and expenses associated with the arbitration. The Customer filed an answer to the complaint denying liability on various grounds and a supplementary answer asserting set-off claims against amounts sought by the Company. The arbitration hearing was held in May 2012, and the Company filed a final brief in July 2012. Due to the complex nature of the legal and factual issues involved, the outcome of the arbitration is uncertain.

Financial Status and Contingencies. As a result of the significant uncertainties on this contract, the Company converted to the completed-contract method of accounting and ceased recognizing revenues for the System development portion of this contract in fiscal 2006. No profits or losses were recorded on the Greek contract during the nine months ended October 31, 2012 and 2011. As of October 31, 2012, the Company has recorded \$123 million of losses under the Greek contract, reflecting the Company's estimated total cost to complete the System, assuming the Greek contract value was limited to the cash received to date. Based on the complex nature of this contractual situation and the difficulties encountered to date, significant uncertainties exist and the Company is unable to reliably estimate the ultimate outcome. The Company may reverse a portion of the losses from the Greek contract if it receives future payments as required under the modified Greek contract.

As of October 31, 2012, the Company has \$15 million of receivables relating to value added tax (VAT) that the Company has paid and believes it is entitled to recover either as a refund from the taxing authorities or as a payment under the Greek

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

contract. The Company has invoiced the Customer for \$32 million for VAT and the Customer has failed to make payment. If the Customer fails to pay the outstanding VAT amounts or the Company is unable to recover the amount as a refund from the taxing authorities, the Company's total losses on the Greek contract could increase.

The Company has met certain advance payment and performance bonding requirements through the issuance of euro-denominated standby letters of credit. As of October 31, 2012, there were \$4 million in standby letters of credit outstanding relating to the support and maintenance of the System. The Company is seeking recovery of amounts drawn by the Customer in fiscal 2011 on the standby letters of credit in the ongoing arbitration. The principal subcontractor has provided to the Company euro-denominated standby letters of credit in the amount of \$22 million as of October 31, 2012, of which \$19 million relates to the delivery of the System. The Company may draw on the subcontractor's standby letters of credit under certain circumstances by providing a statement to the responsible bank that the subcontractor has not fulfilled its obligations under the subcontract.

### **Nuclear Regulatory Commission**

The U.S. Department of Justice filed a lawsuit against the Company in September 2004 in U.S. District Court for the District of Columbia alleging civil False Claims Act violations and breach of contract by the Company on two contracts that the Company had with the Nuclear Regulatory Commission (NRC). The complaint alleges that the Company's performance of several subcontracts on separate U.S. Department of Energy (DOE) programs, the participation of a Company employee in an industry trade association, and certain other alleged relationships created organizational conflicts of interest under the two NRC contracts. The Company disputes that the work performed on the DOE programs and the alleged relationships raised by the government created organizational conflicts of interest. In July 2008, the jury found in favor of the government on the breach of contract and two False Claims Act counts. The jury awarded a nominal amount of \$78 in damages for breach of contract and \$2 million in damages for the False Claims Act claims. The judge entered the judgment in October 2008, trebling the False Claims Act damages and awarding a total of \$585,000 in civil penalties. The Company appealed to the U.S. Court of Appeals for the District of Columbia Circuit. In December 2010, the Court of Appeals affirmed the District Court's judgment as to both liability and damages of \$78 on the breach of contract count and rescinded the judgment on the False Claims Act counts, including the aggregate damages and penalties. The Court of Appeals sent the False Claims Act counts back to the District Court for further proceedings. The Company has recorded a liability for an immaterial amount related to this matter as of October 31, 2012 based on its assessment of the likely outcome of this matter.

#### Other

The Company is also involved in various claims and lawsuits arising in the normal conduct of its business, none of which, in the opinion of the Company's management, based upon current information, will likely have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.

### Note 11—Other Commitments and Contingencies:

## VirnetX, Inc.

In fiscal 2007, the Company transferred several patents to VirnetX Inc., a subsidiary of VirnetX Holding Corp. In consideration of this transfer, the Company received certain license rights and the right to receive a percentage of the consideration received in patent infringement or enforcement claims against third parties. Subsequent to October 31, 2012, a jury found that Apple Corporation infringed two of the patents that the Company previously transferred to VirnetX and awarded approximately \$368 million to VirnetX. Under its agreements with VirnetX, the Company would receive 25% of the proceeds obtained by VirnetX in this lawsuit against Apple after reduction for attorneys' fees and costs incurred in litigating those claims. However, the parties have filed post-trial motions on which the trial court must rule and the verdict may be appealed. Therefore, no assurances can be given when or if the Company will receive any proceeds in connection with this jury award. In addition, if the Company receives any proceeds under its agreements with VirnetX, the Company is required to pay a royalty on the proceeds received to the customer who paid for the development of the technology. The Company does not have any assets or liabilities recorded in connection with this matter as of October 31, 2012.

### **DS&S Joint Venture**

In March 2006, the Company sold its interest in DS&S, a joint venture in which the Company owned a 50% interest. As part of the sale, the Company agreed to indemnify the purchaser or DS&S for certain legal costs and expenses, including those related to a government investigation involving DS&S and any litigation resulting from that investigation. The Company had deferred the potential gain on this sale pending resolution of the government investigation involving DS&S. During the second quarter of fiscal 2013, the Company recorded a gain of \$4 million in other income, net and during the third quarter of fiscal 2013, the Company paid DS&S \$4 million in satisfaction of its indemnification obligation relating to the investigation matter.

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

### Variable Interest Entity (VIE)

In fiscal 2012, the Company entered into a fixed price agreement to provide engineering, procurement, and construction services to a special purpose limited liability company for a specific renewable energy project. The Company analyzed this arrangement and determined the special purpose limited liability company is a VIE. However, this VIE was not consolidated by the Company because the Company is not the primary beneficiary. The project is partially financed by the Company's provision of extended payment terms in the amount of \$100 million for certain of its services performed on the project. The arrangement also contemplates monetary penalties and project guarantees if the Company does not meet certain completion deadlines. The Company expects to bill a total of \$216 million to complete the project. At October 31, 2012, the Company had a receivable of \$27 million due from this VIE.

### **Government Investigations and Reviews**

The Company is routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect to its role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. Adverse findings in these investigations or reviews can lead to criminal, civil or administrative proceedings and the Company could face penalties, fines, repayments or compensatory damages and suspension or debarment from doing business with governmental agencies. Adverse findings could also have a material adverse effect on the Company's business, consolidated financial position, results of operations and cash flows due to its reliance on government contracts.

U.S. Government agencies, including the Defense Contract Audit Agency (DCAA), Defense Contract Management Agency (DCMA) and others, routinely audit and review a contractor's performance on government contracts, indirect rates and pricing practices, and compliance with applicable contracting and procurement laws, regulations and standards. They also review the adequacy of the contractor's compliance with government standards for its accounting and management internal control systems, including: control environment and overall accounting system, estimating system, purchasing system, property system and earned value management system. Both contractors and the U.S. Government agencies conducting these audits and reviews have come under increased scrutiny. As a result, audits and reviews have become more rigorous and the standards to which the Company is held are being more strictly interpreted, increasing the likelihood of an audit or review resulting in an adverse outcome. During the course of its current audits, the DCAA is closely examining and questioning several of the Company's long established and disclosed practices that it had previously audited and accepted, increasing the uncertainty as to the ultimate conclusion that will be reached.

The Company changed its indirect rate structure used in its indirect cost system and its direct labor bid structure used for its estimating system for fiscal 2011 and future years. The DCAA is performing reviews of these changes and the Company's compliance with certain other U.S. Government Cost Accounting Standards. A finding of significant control deficiencies in the Company's system audits or other reviews can result in decremented billing rates to its U.S. Government customers until the control deficiencies are corrected and their remediation is accepted by the DCMA.

The Company's indirect cost audits by the DCAA have not been completed for fiscal 2006 and subsequent fiscal years. Although the Company has recorded contract revenues subsequent to fiscal 2005 based upon an estimate of costs that the Company believes will be approved upon final audit or review, the Company does not know the outcome of any ongoing or future audits or reviews and adjustments, and if future adjustments exceed the Company's estimates, its profitability would be adversely affected. As of October 31, 2012, the Company has recorded a liability of \$35 million for its current best estimate of net amounts to be refunded to customers for potential adjustments from such audits or reviews of contract costs.

## Tax Audits and Reviews

The Company files income tax returns in the United States and various state and foreign jurisdictions and is subject to routine compliance reviews by the IRS and other taxing authorities. The Company has effectively settled with the IRS for fiscal years prior to and including fiscal 2008. The Company also settled fiscal 2011 as a result of the Company's participation in the IRS Compliance Assurance Process (CAP) beginning in fiscal 2011. As part of the CAP, the Company and the IRS endeavor to agree on the treatment of all tax positions prior to the tax return being filed, thereby greatly reducing the period of time between tax return submission and settlement with the IRS. Future and ongoing reviews could have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.

As of October 31, 2012, the Company had liabilities for uncertain tax positions of \$133 million, \$31 million of which were classified as other long-term liabilities in the consolidated balance sheet. Subsequent to October 31, 2012, the Company entered into an issue resolution agreement with the IRS with respect to the tax deductible portion of the CityTime payment

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

described in Note 10 of the combined notes to the condensed consolidated financial statements. The resolution of this tax matter will result in a \$102 million reduction in the Company's uncertain tax positions and a \$96 million reduction in income tax expense during the fourth quarter of fiscal year 2013.

During the next 12 months, it is reasonably possible that resolution of reviews by taxing authorities, both domestic and international, could be reached with respect to \$118 million of the Company's unrecognized tax benefits (including the CityTime issue resolution referenced above) including \$3 million of previously accrued interest, depending on the timing of ongoing examinations, any litigation and expiration of statute of limitations, either because the Company's tax positions are sustained or because the Company agrees to their disallowance and pays the related income tax.

While the Company believes it has adequate accruals for uncertain tax positions, the tax authorities may determine that the Company owes taxes in excess of recorded accruals or the recorded accruals may be in excess of the final settlement amounts agreed to by the tax authorities.

The Company is subject to periodic audits by government agencies for taxes other than income taxes. The Company does not believe that the outcome of any other such tax matters would have a material adverse effect on its consolidated financial position, results of operations, or cash flows

### Letters of Credit and Surety Bonds

The Company has outstanding letters of credit of \$110 million as of October 31, 2012, principally related to guarantees on contracts. The Company also has outstanding surety bonds in the amount of \$302 million, principally related to performance and payment bonds on the Company's contracts.

### Other

The Army Brigade Combat Team Modernization Engineering, Manufacturing and Development program was terminated for convenience by the DoD effective in September 2011. From October 2009 through termination, the Company and its prime contractor performed on this program under an undefinitized change order with a provisional billing rate that allowed the Company to receive a lesser amount of the projected fee than the estimated fee due until completion of the contract negotiations. The Company has recognized revenues of approximately \$480 million, including estimated fee, from October 2009 through October 31, 2012 under the undefinitized change order. During the three months ended October 31, 2012, an agreement in principle was reached between the prime contractor and the DoD. The Company reduced the fees earned under the undefinitized change order by \$2 million during the three months ended October 31, 2012 as a result of this development.

### Note 12—Subsequent Event:

Subsequent to October 31, 2012, the Company's management decided to eliminate approximately 700 positions in order to align its cost structure for greater competitiveness. This management decision will result in an estimated severance charge of approximately \$15 million during the fourth quarter of fiscal year 2013.

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following combined discussion and analysis of SAIC's and Science Applications' financial condition and results of operations and quantitative and qualitative disclosures about market risk should be read in conjunction with our condensed consolidated financial statements and related combined notes. As SAIC is a holding company and consolidates Science Applications for financial statement purposes, disclosures that relate to activities of Science Applications also apply to SAIC, unless otherwise noted. Science Applications' revenues and operating expenses comprise 100% of SAIC's revenues and operating expenses. In addition, Science Applications comprises approximately the entire balance of SAIC's assets, liabilities and operating cash flows. Therefore, the following discussion is applicable to both SAIC and Science Applications, unless otherwise noted.

The following discussion contains forward-looking statements, including statements regarding our intent, belief, or current expectations with respect to, among other things, trends affecting our financial condition or results of operations, backlog, our industry, government budgets, spending and the impact of competition, our intent to create two independent public companies and our expectation that the separation transaction will be a tax-free spin-off. Such statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those in the forward-looking statements as a result of various factors. Some of these factors include, but are not limited to, the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended January 31, 2012, as updated periodically through our subsequent quarterly reports on Form 10-Q. Due to such uncertainties and risks, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update these factors or to publicly announce the results of any changes to our forward-looking statements due to future events or developments.

Except with respect to "Results of Operations—Discontinued Operations" and "—Net Income," and "—Diluted EPS," all amounts in this "Management's Discussion and Analysis of Financial Condition and Results of Operations" are presented for our continuing operations.

We use the terms "Company", "we", "us" and "our" to refer to SAIC, Science Applications and its consolidated subsidiaries. Unless otherwise noted, references to years are for fiscal years ended January 31. For example, we refer to the fiscal year ending January 31, 2013 as "fiscal 2013."

### **Overview**

We are a provider of scientific, engineering, systems integration and technical services and solutions in the areas of defense, health, energy, infrastructure, intelligence, surveillance, reconnaissance and cybersecurity to agencies of the U.S. Department of Defense (DoD), the intelligence community, the U.S. Department of Homeland Security and other U.S. Government civil agencies, state and local government agencies, foreign governments and customers in select commercial markets.

Our business is focused on using deep domain knowledge to solve problems of vital importance to the nation and the world in the areas of national security, energy and the environment, critical infrastructure and health. We are focusing our investments in our strategic growth areas including: intelligence, surveillance and reconnaissance; cybersecurity; logistics, readiness and sustainment; energy and environment; and health information technology. Our significant long-term management initiatives include:

- achieving internal, or non-acquisition related, annual revenue growth through internal collaboration and better leveraging of key differentiators across our company and the deployment of resources and investments into higher growth markets;
- improving our operating income margin through strong contract execution and growth in higher-margin business areas and continued improvement in our information technology (IT) systems infrastructure and related business processes for greater effectiveness and efficiency across all business functions;
- disciplined deployment of our cash resources and use of our capital structure to enhance growth and stockholder value through internal
  growth initiatives, strategic acquisitions, stock repurchases, dividends and other uses as conditions warrant; and
- investing in our people, including enhanced training and career development programs, with a focus on retention and recruiting.

Key financial highlights and events, including progress against management's initiatives, during the three months ended October 31, 2012 include:

Revenues for the three months ended October 31, 2012 increased 3% over the same period in the prior year, reflecting internal revenue growth (as defined in "Non-GAAP Financial Measures") of 1%. Internal revenue growth was driven

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

primarily by increased activity in our Defense Solutions segment partially offset by declines in our Health, Energy and Civil Solutions and Intelligence and Cybersecurity Solutions segments. Revenues for the three months ended October 31, 2011 were negatively impacted by the portion of the loss provision recorded against revenues (\$52 million) in connection with the CityTime matter described in Note 10 of the combined notes to the condensed consolidated financial statements.

- Operating income increased \$213 million to \$193 million (6.7% as a percentage of revenues) for the three months ended October 31, 2012 from an operating loss of \$20 million for the same period in the prior year. The increase in operating income is primarily due to the loss provision (\$232 million) recorded in the prior year in connection with the CityTime matter described in Note 10 of the combined notes to the condensed consolidated financial statements. In addition, operating income for the three months ended October 31, 2012 reflects increased indirect spending (\$15 million), including charges associated with the corporate relocation and the announced separation transaction discussed below, partially offset by fees on increased revenues.
- Income from continuing operations for the three months ended October 31, 2012 increased \$204 million as compared to the same period in the prior year due to the increase in operating income, a decrease in interest expense and a lower effective tax rate.
- Diluted earnings per share (EPS) from continuing operations for the three months ended October 31, 2012 increased \$0.61 as compared to the same period in the prior year primarily due to the increase in income from continuing operations partially offset by an increase in the diluted weighted average number of shares outstanding of 5 million, or 2%.
- Cash and cash equivalents decreased \$225 million during the three months ended October 31, 2012 primarily due to cash used to acquire a business for \$478 million and dividend payments of \$41 million partially offset by cash generated from operations of \$295 million.
- Net bookings (as defined in "Key Financial Metrics—Bookings and Backlog") were approximately \$4.8 billion for the three months ended October 31, 2012. Total backlog was \$18.6 billion at October 31, 2012 as compared to \$16.5 billion at July 31, 2012.

### **Planned Separation Transaction**

In August 2012, we announced that our board of directors authorized management to pursue a plan to separate into two independent, publicly traded companies: (i) a company focused on government technology and enterprise information technology services; and (ii) a company focused on delivering science and technology solutions primarily in the areas of national security, engineering and health.

The proposed separation is intended to take the form of a tax-free spin-off of the government technology and enterprise information technology services business. The separation transaction is expected to occur in the latter half of calendar year 2013, subject to final approval of the board of directors and certain other conditions. The separation transaction is not expected to require a vote of the stockholders of SAIC.

Management is continuing to develop detailed plans on capital structure, management, governance and other significant matters. In addition, the completion of any separation transaction will be subject to certain customary conditions, including implementation of intercompany agreements, filing of required documents with the U.S. Securities and Exchange Commission and receipt of an opinion from tax counsel and a ruling from the Internal Revenue Service (IRS) as to the tax-free nature of such a transaction. Although we expect that the separation of our businesses, if consummated, would be completed in the latter half of calendar year 2013, there can be no assurance that a separation will ultimately occur. Upon completion of the separation transaction, the operating results of the separated business will be included in discontinued operations. See "Part II, Item 1A—Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2012 for certain risk factors relating to the proposed separation transaction.

### **Business Environment and Trends**

In fiscal 2012, we generated over 90% of our total revenues from contracts with the U.S. Government, either as a prime contractor or a subcontractor to other contractors engaged in work for the U.S. Government. Revenues under contracts with the DoD, including subcontracts under which the DoD is the ultimate purchaser, represented approximately 75% of our total revenues in fiscal 2012. Accordingly, our business performance is subject to changes in the overall level of U.S. Government spending, especially national security, including defense, homeland security, and intelligence spending, and the alignment of our service and product offerings and capabilities with current and future budget priorities of the U.S. Government.

While we believe that national security, including defense, homeland security, and intelligence spending will continue to be a priority, the U.S. Government deficit and budget situation has created increasing pressure to examine and reduce spending in these areas. In August 2011, President Obama signed into law the Budget Control Act of 2011, which increased the U.S. Government's debt ceiling and enacted 10-year discretionary spending caps expected to generate over \$1 trillion in savings

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

for the U.S. Government. According to the Office of Management and Budget, these savings include \$487 billion in DoD baseline spending reductions over the next 10 years. The Budget Control Act of 2011 also established a joint bipartisan committee of Congress responsible to recommend at least \$1.2 trillion in additional savings by November 2011. The joint committee did not meet the deadline for proposing recommended legislation. Unless the Budget Control Act of 2011 is amended, additional automatic spending cuts (referred to as sequestration) totaling \$1.2 trillion over nine years will be triggered. Assuming approximately \$200 billion in reduced debt-service costs, these discretionary spending cuts are expected to be evenly split between defense and non-defense areas, reducing spending for each area by approximately \$500 billion over a nine-year period, beginning in the government fiscal year ending September 30, 2013 (GFY13). In September 2012, the Office of Management and Budget delivered to Congress a report detailing how sequestration would be implemented. While the report included estimated GFY13 reductions by discretionary budget account, it failed to describe how reductions would occur at levels below the account level (i.e., at the project, program and activity level). As a result, there remains significant uncertainty about how the federal government would implement sequestration, currently set to begin in January 2013. Following the November 2012 elections, while the possibility of sequestration, as well as scheduled tax expirations, and other issues associated with the "fiscal cliff" continues to be the top priority for the Obama Administration and Congress, we cannot predict the outcome of any ongoing discussions to address these matters. We continue to evaluate the potential impact of possible sequestration on our business, and while the ultimate effect on our business is uncertain, the amount and nature of these federal budget spending reductions could adversely impact our operations, future revenu

A U.S. Government budget for GFY13 has not been passed by Congress. Instead, Congress passed, and the President signed, a six-month continuing resolution funding the U.S. Government through March 31, 2013. While the continuing resolution averts a government shutdown and removes GFY13 funding as a major issue to be solved during the current lame duck session of Congress, it also contains standard restrictions, including no new program starts and no program increases beyond current service levels which could limit our ability to grow our business. We continue to evaluate the ongoing GFY13 budget negotiations, including the potential deferral or prevention of sequestration, and the possible impact on our operations, future revenues and growth prospects.

Competition for contracts with the U.S. Government continues to be intense. The U.S. Government has increasingly used contracting processes that give it the ability to select multiple winners or pre-qualify certain contractors to provide various services or products at established general terms and conditions. Such processes include purchasing services and solutions using indefinite-delivery/indefinite-quantity (IDIQ) and U.S. General Services Administration (GSA) contract vehicles. This trend has served to increase competition for U.S. Government contracts. For more information on these risks and uncertainties, see "Risk Factors" in Part I of our Annual Report on Form 10-K for the fiscal year ended January 31, 2012, as updated through our subsequent quarterly reports on Form 10-Q.

### **Reportable Segments**

Our business is aligned into four reportable segments: Defense Solutions; Health, Energy and Civil Solutions; Intelligence and Cybersecurity Solutions; and Corporate and Other. For additional information regarding our reportable segments, see Note 9 of the combined notes to the condensed consolidated financial statements for the three and nine months ended October 31, 2012 contained in this Quarterly Report on Form 10-Q, and "Business" in Part I and Note 15 of the combined notes to consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal year ended January 31, 2012.

# **Key Financial Metrics**

Bookings and Backlog. We received net bookings worth an estimated \$4.8 billion and \$9.1 billion during the three and nine months ended October 31, 2012, respectively. Net bookings represent the estimated amount of revenues to be earned in the future from funded and unfunded contract awards that were received during the period, net of any adjustments to previously awarded backlog amounts. We calculate net bookings as the period's ending backlog plus the period's revenues less the prior period's ending backlog and less the backlog obtained in acquisitions during the period.

Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts as work is performed and excludes contract awards which have been protested by competitors. We segregate our backlog into two categories as follows:

Funded Backlog. Funded backlog for contracts with government agencies primarily represents contracts for which funding is appropriated less revenues previously recognized on these contracts, and does not include the unfunded portion of contracts where funding is incrementally appropriated or authorized on a quarterly or annual basis by the U.S. Government and other customers, even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government agencies represents the estimated value on contracts, which may cover multiple future years, under which we are obligated to perform, less revenues previously recognized on these contracts.

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Negotiated Unfunded Backlog. Negotiated unfunded backlog represents estimated amounts of revenues to be earned in the future from
 (1) negotiated contracts for which funding has not been appropriated or otherwise authorized and (2) unexercised priced contract options.
 Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under IDIQ, GSA
 Schedule, or other master agreement contract vehicles.

The estimated value of our total backlog as of the dates presented was as follows:

	O	ctober 31, July 31 2012 2012		April 30, 2012	Janu	uary 31, 2012
		(in millions)				
Defense Solutions:						
Funded backlog	\$	2,174	\$ 2,013	\$ 2,026	\$	2,143
Negotiated unfunded backlog		4,563	4,309	4,605		4,961
Total Defense Solutions backlog	\$	6,737	\$ 6,322	\$ 6,631	\$	7,104
Health, Energy and Civil Solutions:						
Funded backlog	\$	1,842	\$ 1,858	\$ 1,911	\$	2,057
Negotiated unfunded backlog		2,854	2,865	3,061		3,238
Total Health, Energy and Civil Solutions backlog	\$	4,696	\$ 4,723	\$ 4,972	\$	5,295
Intelligence and Cybersecurity Solutions:						
Funded backlog	\$	1,705	\$ 1,615	\$ 1,752	\$	1,317
Negotiated unfunded backlog		5,440	3,867	3,880		4,169
Total Intelligence and Cybersecurity Solutions backlog	\$	7,145	\$ 5,482	\$ 5,632	\$	5,486
Total:						
Funded backlog	\$	5,721	\$ 5,486	\$ 5,689	\$	5,517
Negotiated unfunded backlog		12,857	11,041	11,546	1	2,368
Total backlog	\$	18,578	\$16,527	\$17,235	\$ 1	7,885

Total backlog fluctuates from period to period depending on our success rate in winning contracts and the timing of contract awards, renewals, modifications and cancellations. Contract awards continue to be negatively impacted by on-going industry-wide delays in procurement decisions, which have resulted in an increase in the value of our submitted proposals awaiting decision. Backlog may also be negatively impacted by possible sequestration by the U.S. Government as discussed in "Business Environment and Trends" in this Quarterly Report on Form 10-Q.

We expect to recognize a substantial portion of our funded backlog as revenues within the next 12 months. However, the U.S. Government may cancel any contract at any time. In addition, certain contracts with commercial customers include provisions that allow the customer to cancel at any time. Most of our contracts have cancellation terms that would permit us to recover all or a portion of our incurred costs and fees for work performed.

Contract Types. Our earnings and profitability may vary materially depending on changes in the proportionate amount of revenues derived from each type of contract. For additional information regarding the types of contracts under which we generate revenues, see "Business—Contract Types" in Part I of our Annual Report on Form 10-K for the fiscal year ended January 31, 2012. The following table summarizes revenues by contract type as a percentage of total revenues for the periods presented:

	Nine Months End	ded October 31
	2012	2011
Cost-reimbursement	42%	45%
Time and materials (T&M) and fixed-price-level-of-effort (FP-LOE)	29	30
Firm-fixed price (FFP)	29	25
Total	100%	100%

The increase in the percentage of revenues generated from FFP contracts during the nine months ended October 31, 2012 as compared to the same period of the prior year was primarily due to increased revenues from increased deliveries under certain logistics, readiness and sustainment contracts, increased design and construction services and increased activity on a program to operate and maintain the enterprise network IT infrastructure for the U.S. Department of State.

Revenue Mix. We generate revenues under our contracts from (1) the efforts of our technical staff, which we refer to as labor-related revenues, and (2) the materials provided on a contract and efforts of our subcontractors, which we refer to as

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

M&S revenues. M&S revenues are generated primarily from large, multi-year systems integration contracts and contracts in our logistics, readiness and sustainment business area, as well as through sales of our proprietary products, such as our border, port and mobile security products and our checked baggage explosive detection systems. While our proprietary products are more profitable, these products represent a small percentage of our M&S revenues and the majority of our M&S revenues generally have lower margins than our labor-related revenues. The following table presents changes in labor-related revenues and M&S revenues for the periods presented:

	Three Mor	Three Months Ended October 31				ober 31	
		Percent			Percent		
	2012	change	2011	2012	change	2011	
		(dollars in m					
Labor-related revenues	\$1,562	1%	\$1,546	\$4,558	— %	\$4,570	
As a percentage of revenues	54%		55%	54%		57%	
M&S revenues	1,308	5	1,244	3,904	13	3,456	
As a percentage of revenues	46%		45%	46%		43%	

In recent years, there have been increases in the relative proportion of M&S revenues as compared to labor-related revenues primarily due to increased activity as a prime contractor on large programs involving significant subcontracted efforts and increased volume of material deliveries under certain programs, primarily with DoD customers.

### **Results of Operations**

The following table summarizes our results of operations for the periods presented:

	Three Months Ended October 31			Nine Months Ended October 31			
	Percent				Percent		
	2012	change	2011	2012	change	2011	
			(dollars in	millions)			
Revenues	\$2,870	3%	\$2,790	\$8,462	5%	\$8,026	
Cost of revenues	2,509	1	2,477	7,429	5	7,051	
Selling, general and administrative expenses (SG&A):							
General and administrative (G&A)	103	(62)	269	248	(36)	386	
Bid and proposal (B&P)	37	(3)	38	132	16	114	
Internal research and development (IR&D)	17	(35)	26	49	(21)	62	
Separation transaction expenses	11	100	_	15	100	_	
Operating income (loss)	193	1,065	(20)	589	43	413	
Operating income margin	6.7%		(0.7)%	7.0%		5.1%	
Non-operating expense, net	(16)		(29)	(59)		(79)	
Income (loss) from continuing operations before income taxes	177	461	(49)	530	59	334	
Provision for income taxes	(65)	51	(43)	(193)	3	(188)	
Income (loss) from continuing operations	112	222	(92)	337	131	146	
Income from discontinued operations, net of tax	_		` 3	2		74	
Net income (loss)	\$ 112	226	\$ (89)	\$ 339	54	\$ 220	

We classify indirect costs incurred within or allocated to our government customers as overhead (included in cost of revenues) and G&A expenses in the same manner as such costs are defined in our disclosure statements under U.S. Government Cost Accounting Standards.

Changes in Estimates on Contracts. Changes in estimates related to certain types of contracts accounted for using the percentage of completion method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes. Changes in these estimates can routinely occur over the contract performance period for a variety of reasons, including changes in contract scope, changes in contract cost estimates due to unanticipated cost growth or retirements of risk for amounts different than estimated, and changes in estimated incentive or award fees. Aggregate changes in contract estimates increased operating income by \$8 million (\$0.01 per diluted share) and \$9 million (\$0.01 per diluted share) for the three and nine months ended October 31, 2012, respectively. Aggregate changes in contract estimates increased operating income by \$6 million (\$0.01 per diluted share) and \$33 million (\$0.06 per diluted share) for the three and nine months ended October 31, 2011, respectively.

Reportable Segment Results. Effective February 1, 2012, certain operations were transferred between the Company's reportable segments. Prior year amounts have been adjusted for consistency with the current year's presentation.

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

The following table summarizes changes in Defense Solutions revenues and operating income for the periods presented:

	Three M	onths Ended Oct	ober 31	Nine Months Ended October 31			
		Percent			Percent		
Defense Solutions	2012	change	2011	2012	change	2011	
		(dollars in millions)					
Revenues	\$1,183	6%	\$1,117	\$3,597	8%	\$3,339	
Operating income (loss)	91	168	(133)	284	531	45	
Operating income (loss) margin	7.7%		(11.9)%	7.9%		1.3%	

Defense Solutions revenues increased by \$66 million, or 6%, all of which was internal revenue growth, for the three months ended October 31, 2012 as compared to the same period in the prior year. Revenues for the three months ended October 31, 2011 were negatively impacted by the portion of the loss provision recorded against revenues in connection with the CityTime matter (\$52 million). See Note 10 of the combined notes to the condensed consolidated financial statements. Internal revenue growth for the three months ended October 31, 2012 was also attributable to increased activity on a number of programs, including the Vanguard program to operate and maintain the enterprise network IT infrastructure for the U.S. Department of State (\$42 million) and the ramp up of a prime contract with the Defense Logistics Agency to provide supply chain management of military land and aircraft tires (\$47 million). These increases were partially offset by reduced revenue from the U.S. Army Brigade Combat Team Modernization (BCTM) contract as a result of the program's termination during the third quarter of fiscal 2012 (\$34 million).

Defense Solutions revenues increased by \$258 million, or 8%, all of which was internal revenue growth, for the nine months ended October 31, 2012 as compared to the same period in the prior year. Revenues for the nine months ended October 31, 2011 were negatively impacted by the portion of the loss provision recorded against revenues in connection with the CityTime matter (\$52 million). Internal revenue growth for the nine months ended October 31, 2012 was also attributable to increased activity on a number of programs, including the Vanguard program to operate and maintain the enterprise network IT infrastructure for the U.S. Department of State (\$121 million), the AMCOM Express systems and software development program for the U.S. Army (\$117 million), a systems integration and logistics program for tactical and mine resistant ambush protected vehicles (\$48 million), and the ramp up of a prime contract with the Defense Logistics Agency to provide supply chain management of military land and aircraft tires (\$107 million). There was also one additional business day as compared to the same period in the prior year (\$18 million). These increases were partially offset by reduced revenue from the BCTM contract as a result of the program's termination during the third quarter of fiscal 2012 (\$144 million).

Defense Solutions operating income increased \$224 million for the three months ended October 31, 2012 as compared to the same period in the prior year. Operating income for the three months ended October 31, 2011 was negatively impacted by the loss provision recorded in connection with the CityTime matter (\$232 million). Additionally, operating income for the three months ended October 31, 2012 benefitted from the favorable changes in contract estimates (\$5 million) offset by a gain in the prior year period on the sale of certain assets previously used in developing guidance and navigation control systems for precision munitions (\$5 million).

Defense Solutions operating income increased \$239 million for the nine months ended October 31, 2012 as compared to the same period in the prior year. Operating income for the nine months ended October 31, 2011 was negatively impacted by the loss provision recorded in connection with the CityTime matter (\$232 million). Additionally, operating income for the nine months ended October 31, 2012 increased due to fees on increased revenues (\$16 million) partially offset by a gain in the prior year period on the sale of certain assets previously used in developing guidance and navigation control systems for precision munitions (\$5 million) as well as a \$4 million increase in B&P and IR&D spending in the current year.

The following table summarizes changes in Health, Energy and Civil Solutions revenues and operating income for the periods presented:

	Three M	onths Ended Oct	ober 31	Nine Mo	ober 31	
		Percent			Percent	
Health, Energy and Civil Solutions	2012	change	2011	2012	change	2011
	(dollars in millions)					
Revenues	\$ 743	2%	\$ 726	\$2,077	4%	\$1,997
Operating income	69	(10)	77	168	(10)	187
Operating income margin	9.3%		10.6%	8.1%		9.4%

Health, Energy and Civil Solutions revenues increased \$17 million, or 2%, for the three months ended October 31, 2012 as compared to the same period in the prior year primarily due to the August 2012 acquisition of maxIT Healthcare Holdings, Inc.

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

and the August 2011 acquisition of Vitalize Consulting Solutions, Inc. Internal revenue contracted 4% reflecting declines in various federal civilian programs (\$41 million) and program completions with federal health information technology customers, particularly with U.S. DoD military health system customers (\$29 million). These declines were partially offset by an increase in healthcare IT consulting services with commercial clients (\$58 million).

Health, Energy and Civil Solutions revenues increased \$80 million, or 4%, for the nine months ended October 31, 2012 as compared to the same period in the prior year primarily due to the August 2012 acquisition of maxIT Healthcare Holdings, Inc. and the August 2011 acquisition of Vitalize Consulting Solutions, Inc. Internal revenue contracted 2% reflecting declines in various federal civilian programs (\$76 million) and program completions with federal health information technology customers, particularly with U.S. DoD military health system customers (\$73 million). These declines were partially offset by increases in healthcare IT consulting services with commercial clients (\$85 million) and increased design-build volume related to various power plant construction projects (\$21 million). There was also one additional business day as compared to the same period in the prior year (\$11 million).

Health, Energy and Civil Solutions operating income decreased \$8 million, or 10%, for the three months ended October 31, 2012 as compared to the same period in the prior year. The decline in operating income was primarily due to a net unfavorable change in contract estimates (\$1 million) compared to a net positive change in contract estimates (\$3 million) in the prior year period, increased bid and proposal expense (\$3 million), increased amortization expense associated with acquired intangible assets (\$3 million) and reduced volume in our higher margin non-intrusive inspection business. These decreases were partially offset by reduced research and development expense (\$5 million) resulting from the advancement through the product development lifecycle of new non-intrusive inspection system offerings.

Health, Energy and Civil Solutions operating income decreased \$19 million, or 10%, for the nine months ended October 31, 2012 as compared to the same period in the prior year. The decline in operating income was primarily due to a net unfavorable change in contract estimates (\$9 million) primarily related to certain energy and construction projects compared to a net positive change in contract estimates (\$11 million) in the prior year period, increased amortization expense associated with acquired intangible assets (\$4 million), and a \$2 million increase in bid and proposal expense. This decrease was partially offset by a \$13 million reduction in research and development expense resulting from the advancement through the product development lifecycle of new non-intrusive inspection system offerings and fees on increased revenues (\$6 million).

The following table summarizes changes in Intelligence and Cybersecurity Solutions revenues and operating income for the periods presented:

	Three Mo	Three Months Ended October 31			Nine Months Ended October 31			
	<u> </u>	Percent			Percent			
Intelligence and Cybersecurity Solutions	2012	change	2011	2012	change	2011		
			(dollars in millions)					
Revenues	\$ 945	%	\$ 947	\$2,792	4%	\$2,691		
Operating income	68	26	54	203	(6)	215		
Operating income margin	7.2%		5.7%	7.3%		8.0%		

Intelligence and Cybersecurity Solutions revenues decreased \$2 million, all of which was internal revenue contraction, for the three months ended October 31, 2012 as compared to the same period in the prior year. Internal revenue contraction was primarily attributable to reduced activity on a processing, exploitation and dissemination program for the U.S. Army (\$47 million), including a non-recurring material delivery of \$38 million under the program in the prior year. These declines were partially offset by increased activity, primarily a significant materials purchase, on a geospatial intelligence program (\$28 million) and increased activity on an airborne surveillance program (\$15 million).

Intelligence and Cybersecurity Solutions revenues increased \$101 million, or 4%, all of which was internal revenue growth, for the nine months ended October 31, 2012 as compared to the same period in the prior year. Internal revenue growth was primarily attributable to increased activity on two airborne surveillance programs (\$87 million), increased activity, including a significant materials purchase, on a geospatial intelligence program (\$42 million), a new intelligence systems integration program for the U.S. Army (\$22 million), and a new intelligence and analysis solution program (\$25 million). There was also one additional business day as compared to the same period in the prior year (\$14 million). These increases were partially offset by reduced activity on a processing, exploitation and dissemination program for the U.S. Army (\$60 million), and an intelligence analysis contract that concluded in the current year (\$21 million).

Intelligence and Cybersecurity Solutions operating income increased \$14 million, or 28%, for the three months ended October 31, 2012 as compared to the same period in the prior year. The increase in operating income was primarily

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

attributable to the prior year period \$19 million impairment of acquired intangible assets as compared to \$1 million in the current year period and an \$8 million current year period reduction in indirect spending, primarily related to the timing of B&P and IR&D spending. The level of B&P activity fluctuates from period to period depending on the nature and timing of bidding opportunities. This was partially offset by reduced profitability on certain contracts due to increased subcontractor and material costs.

Intelligence and Cybersecurity Solutions operating income decreased \$12 million, or 6%, for the nine months ended October 31, 2012 as compared to the same period in the prior year. The decrease in operating income was primarily attributable to lower profitability (\$12 million) on certain contracts due to increased material and subcontractor costs and the completion of an intelligence gathering and analysis program, a \$7 million increase in indirect spending, primarily related to the timing of B&P and IR&D spending, a decline in sales of our higher-margin proprietary products (\$11 million), and a reduction in net positive changes in contract estimates (\$3 million). The level of B&P activity fluctuates from period to period depending on the nature and timing of bidding opportunities. These decreases were partially offset by the prior year period \$19 million impairment of acquired intangible assets as compared to \$2 million in the current year period, decreased amortization of intangible assets acquired (\$5 million) and fees on increased revenues (\$7 million).

The following table summarizes changes in Corporate and Other revenues and operating loss for the periods presented:

	7	Three Months Ended October 31				Nine Months Ended October 31			
Corporate and Other		2012		2011		2012		2011	
			(dollars in millions)						
Revenues	\$		\$	1	\$	_	\$	2	
Operating loss	\$	(35)	\$	(18)	\$	(66)	\$	(34)	

Corporate and Other operating loss for the three and nine months ended October 31, 2012 represents corporate costs that are unallowable under U.S. Government Cost Accounting Standards and the net effect of various items that are not directly related to the operating performance of the reportable segments. Corporate and Other operating loss increased by \$17 million and \$32 million for the three and nine months ended October 31, 2012, respectively, as compared to the same periods of the prior year primarily due to relocation and severance charges for the transition of corporate functions to our McLean, Virginia headquarters and other locations (\$4 million and \$13 million for the three and nine months ended October 31, 2012, respectively) in addition to costs associated with the planned separation transaction (\$11 million and \$15 million for the three and nine months ended October 31, 2012, respectively). Corporate and Other operating loss for the nine months ended October 31, 2011 also included gains on the sale of real estate of \$28 million partially offset by charges related to the settlement of a litigation matter of \$22 million and other recurring items.

Interest Expense. Interest expense for the three and nine months ended October 31, 2012 decreased \$9 million and \$12 million, respectively, as compared to the same periods of the prior year primarily due to the payment of \$550 million in July 2012 to settle the 6.25% notes at maturity.

Interest expense for Science Applications decreased \$10 million for the three months ended October 31, 2012 as compared to the same period of the prior year, reflecting a \$1 million decrease in interest on its note with SAIC and a \$9 million decrease in interest on third-party debt, which was primarily due to the payment of the \$550 million notes discussed above. Interest expense for Science Applications decreased \$17 million for the nine months ended October 31, 2012 as compared to the same period of the prior year, reflecting a \$5 million decrease in interest on its note with SAIC and a \$12 million decrease in interest on third-party debt. Interest expense related to Science Application's note with SAIC may fluctuate significantly from year to year based on changes in the underlying note balance and interest rates throughout the fiscal year.

Provision for Income Taxes. The provision for income taxes increased \$22 million to \$65 million (36.7% as a percentage of income from continuing operations before income taxes) for the three months ended October 31, 2012 as compared to the same period in the prior year. The prior year period provision for income taxes includes the effect of the estimated non-deductible portion of the CityTime loss provision recorded in the prior year quarter. The current year period provision for income taxes includes the deductibility of quarterly dividends paid on shares held by the SAIC Retirement Plan (an employee stock ownership plan) partially offset by a decrease in the domestic manufacturer's deduction and expiration of the federal research and development tax credit on December 31, 2011.

The provision for income taxes as a percentage of income from continuing operations before income taxes was 36.4% and 56.3% for the nine months ended October 31, 2012 and 2011, respectively. The decrease in the provision for income taxes as a percentage of income from continuing operations was primarily attributable to the estimated non-deductible portion of the CityTime loss provision recorded in the prior year period, a change in the estimated deductible amount of a prior year legal settlement and the tax deductibility of quarterly dividends paid on shares held by the SAIC Retirement Plan (an employee stock ownership plan), partially offset by a decrease in the domestic manufacturer's deduction and expiration of the federal research and development tax credit on December 31, 2011.

### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

We file income tax returns in the United States and various state and foreign jurisdictions and have effectively settled with the IRS for fiscal years prior to and including fiscal 2008. We also settled fiscal 2011 as a result of our participation in the IRS Compliance Assurance Process (CAP) beginning in fiscal 2011. As part of the CAP, we endeavor to agree with the IRS on the treatment of all tax positions prior to the filing of the tax return, thereby greatly reducing the period of time between return submission and settlement with the IRS.

As of October 31, 2012, we had liabilities for uncertain tax positions of \$133 million, \$31 million of which were classified as other long-term liabilities in the consolidated balance sheet. Subsequent to October 31, 2012, we entered into an issue resolution agreement with the IRS with respect to the tax deductible portion of the CityTime payment. The resolution of this tax matter will result in a \$102 million reduction in our uncertain tax positions and a \$96 million reduction in income tax expense during the fourth quarter of our fiscal year 2013.

Diluted Earnings per Share (EPS) from Continuing Operations. Diluted EPS from continuing operations increased \$0.61 per share to \$0.33 per share for the three months ended October 31, 2012 as compared to the same period in the prior year primarily due to the increase in income from continuing operations primarily attributable the impact of the CityTime loss provision in the prior year period partially offset by a 5 million, or 2%, increase in the diluted weighted average number of shares outstanding. Diluted EPS from continuing operations increased \$0.57 per share to \$0.99 per share for the nine months ended October 31, 2012 as compared to the same period in the prior year due to the increase in income from continuing operations primarily attributable to the impact of the CityTime loss provision in the prior year period in addition to a 6 million, or 2%, decline in the diluted weighted average number of shares outstanding due to stock repurchases in previous quarters.

Discontinued Operations. From time to time, we may dispose (or management may commit to plans to dispose) of non-strategic components of our business, which are reclassified as discontinued operations for all periods presented.

In November 2012, we sold certain components of our business, which were historically included in the Health, Energy and Civil Solutions segment, primarily focused on providing operational test and evaluation services.

In fiscal 2012, in order to better align our business portfolio with our strategy, we sold certain components of our business, which were historically included in the Health, Energy and Civil Solutions segment, primarily focused on providing information technology services to international oil and gas companies. We received net proceeds of \$167 million resulting in a gain on sale before income taxes of \$111 million related to this sale. Under terms of the definitive agreement, we retained the assets and obligations of our defined benefit pension plan in the United Kingdom. We have classified the operating results of these business components, including pension expense through the date of sale, as discontinued operations. Following the asset sale, as a result of retaining the pension obligation, the remaining components of ongoing pension expense, primarily interest costs and assumed return on plan assets, are recorded in continuing operations.

The pre-sale operating results of these discontinued operations were as follows:

	Nine Mo	Nine Months Ended October 31				
	2012	2011				
		(in millions)				
Revenues	\$ 55	\$ 140				
Costs and expenses:						
Cost of revenues	48	114				
Selling, general and administrative expenses	3	12				
Operating income	\$ 4	\$ 14				

Income from discontinued operations also includes other activity that is immaterial and not reflected in the amounts above.

Net Income. Net income increased \$201 million and \$119 million for the three and nine months ended October 31, 2012, respectively, as compared to the same periods in the prior year. The increases in net income for the three and nine months ended October 31, 2012 as compared to the same periods in the prior year are primarily due to an increase in income from continuing operations partially offset by a decrease in income from discontinued operations.

Net income for Science Applications increased \$203 million and \$122 million for the three and nine months ended October 31, 2012, respectively, as compared to the same periods in the prior year for the reasons described above.

Diluted EPS. Diluted EPS increased \$0.60 per share to \$0.33 per share and \$0.37 per share to \$1.00 per share for the three and nine months ended October 31, 2012, respectively, as compared to the same periods in the prior year primarily due to the reasons discussed above for diluted EPS from continuing operations.

#### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

#### **Subsequent Event**

Subsequent to October 31, 2012, our management decided to eliminate approximately 700 positions in order to align our cost structure for greater competitiveness. This management decision will result in an estimated severance charge of approximately \$15 million during the fourth quarter of fiscal year 2013.

## **Liquidity and Capital Resources**

We had \$531 million in cash and cash equivalents at October 31, 2012, which were primarily comprised of cash held in insured bank deposits and investments in several large institutional money market funds that invest primarily in bills, notes and bonds issued by the U.S. Treasury, U.S. Government guaranteed repurchase agreements fully collateralized by U.S. Treasury obligations, U.S. Government guaranteed securities and investment-grade corporate securities that have original maturities of three months or less. We anticipate our principal sources of liquidity for the next 12 months and beyond will be our existing cash and cash equivalents and cash flows from operations. We may also borrow under our \$750 million revolving credit facility. Our revolving credit facility is backed by a number of financial institutions, matures in fiscal 2017 and, by its terms, can be accessed on a same-day basis. We anticipate our principal uses of cash for the next 12 months and beyond will be for operating expenses, expenses related to the planned separation transaction, capital expenditures, acquisitions of businesses, stock repurchases and dividends. We anticipate that our operating cash flows, existing cash and cash equivalents, which have no restrictions on withdrawal, and borrowing capacity under our revolving credit facility will be sufficient to meet our anticipated cash requirements for at least the next 12 months.

#### **Historical Trends**

Cash and cash equivalents was \$531 million and \$1.592 billion at October 31, 2012 and January 31, 2012, respectively. The following table summarizes cash flow information for the periods presented:

		Nine Months En	iaea Octobe	er 31
		2012		2011
	(in millions)			
Total cash flows provided by operating activities of continuing operations	\$	134	\$	627
Total cash flows used in investing activities of continuing operations		(517)		(185)
Total cash flows used in financing activities of continuing operations		(683)		(454)
Increase in cash and cash equivalents from discontinued operations		5		107
Effect of foreign exchange rate changes on cash and cash equivalents		_		1
Total increase (decrease) in cash and cash equivalents	\$	(1,061)	\$	96

Cash Provided by (Used in) Operating Activities of Continuing Operations. Cash flows from operating activities of continuing operations decreased \$493 million for the nine months ended October 31, 2012 as compared to the same period in the prior year. Cash flows from operating activities of continuing operations were primarily impacted by a \$500 million cash settlement payment related to the CityTime program described in Note 10 of the combined notes to the condensed consolidated financial statements and an additional payroll payment made in the current year period partially offset by a reduction in the average time to collect receivables. Days sales outstanding were 61 days for the three months ended October 31, 2012 compared to 71 days for the same period in the prior year.

Any differences in cash flows from operating activities of continuing operations for Science Applications as compared to SAIC are primarily attributable to changes in interest payments made on the related party note.

Cash Used in Investing Activities of Continuing Operations. We used \$517 million of cash in support of investing activities of continuing operations during the nine months ended October 31, 2012, including \$478 million to acquire a business and \$43 million to purchase property, plant and equipment. We used \$185 million of cash in support of investing activities of continuing operations during the nine months ended October 31, 2011 including \$216 million to acquire two businesses and \$48 million to purchase property, plant and equipment, partially offset by \$78 million of proceeds from the sale of real estate.

Cash Used in Financing Activities of Continuing Operations. We used \$683 million of cash in support of financing activities of continuing operations during the nine months ended October 31, 2012, including \$550 million to settle notes payable at maturity in July 2012, payment of dividends of \$124 million and \$21 million to repurchase shares of our stock. We used \$454 million of cash in support of financing activities of continuing operations during the nine months ended October 31, 2011, including \$470 million to repurchase shares of our stock.

Science Applications used cash in financing activities of continuing operations of \$883 million during the nine months ended October 31, 2012, including \$550 million to settle notes payable at maturity in July 2012 and repayments on the related party note with SAIC of \$369 million partially offset by proceeds from the related party note with SAIC of \$40 million. Science

#### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Applications used cash from financing activities of continuing operations of \$451 million during the nine months ended October 31, 2011, including repayments on the related party note with SAIC of \$1.047 billion partially offset by proceeds from the related party note with SAIC of \$601 million.

Cash Flows from Discontinued Operations. Cash flows from discontinued operations for the nine months ended October 31, 2011 included proceeds of \$168 million from the sale of certain components of our business.

#### Stock Repurchase Program

In March 2012, our board of directors authorized a stock repurchase program under which we may repurchase up to 40 million shares of SAIC common stock. Stock repurchases may be made on the open market or in privately negotiated transactions with third-parties. Whether repurchases are made and the timing and actual number of shares repurchased depends on a variety of factors including price, corporate capital requirements, other market conditions and regulatory requirements.

#### **Outstanding Indebtedness**

Notes Payable and Long-term Debt. Our outstanding notes payable and long-term debt consisted of the following:

	Effective				
Stated	interest	Oct		Jai	nuary 31,
interest rate	rate				2012
(dollars in millions)					
4.45%	4.53%	\$	449	\$	449
5.95%	6.03%		300		300
6.25%	6.50%		_		550
7.13%	7.43%		248		248
5.50%	5.78%		296		296
0-2.5%	Various		6		9
			1,299		1,852
			2		553
		\$	1,297	\$	1,299
		\$	1,449	\$	2,011
	4.45% 5.95% 6.25% 7.13% 5.50%	Stated interest rate         interest rate (dollars in ate)           4.45%         4.53%           5.95%         6.03%           6.25%         6.50%           7.13%         7.43%           5.50%         5.78%	Stated interest rate         interest rate         Oct rate           (dollars in millions)         4.45%         4.53%         \$           5.95%         6.03%         \$           6.25%         6.50%         7.13%         7.43%           5.50%         5.78%           0-2.5%         Various         \$	Stated interest rate         interest rate         October 31, rate         2012           (dollars in millions)           4.45%         4.53%         \$ 449           5.95%         6.03%         300           6.25%         6.50%         —           7.13%         7.43%         248           5.50%         5.78%         296           0-2.5%         Various         6           1,299         2           \$ 1,297         \$ 1,297	Stated interest rate         interest rate         October 31, rate         Jan 2012           (dollars in millions)           4.45%         4.53%         \$ 449         \$ 5.95%           6.03%         300         \$ 6.25%         6.50%         —           7.13%         7.43%         248         5.50%         5.78%         296           0-2.5%         Various         6         1,299         2           \$ 1,297         \$         \$ 1,297         \$

We paid \$550 million to settle the 6.25% notes at maturity in July 2012.

These notes contain financial covenants and customary restrictive covenants, including, among other things, restrictions on our ability to create liens and enter into sale and leaseback transactions. We were in compliance with all covenants as of October 31, 2012.

Credit Facility. SAIC has a revolving credit facility, which is fully and unconditionally guaranteed by Science Applications, providing for up to \$750 million in unsecured borrowing capacity at interest rates determined, at SAIC's option, based on either LIBOR plus a margin or a defined base rate through March 2016. As of October 31, 2012 and January 31, 2012, there were no borrowings outstanding under the revolving credit facility. The revolving credit facility contains financial covenants and customary restrictive covenants. We were in compliance with all covenants under the revolving credit facility as of October 31, 2012. A failure to meet the financial covenants in the future would reduce and could eliminate our borrowing capacity under the revolving credit facility.

## **Off-Balance Sheet Arrangements**

We have outstanding performance guarantees and cross-indemnity agreements in connection with certain of our unconsolidated joint venture investments. We also have letters of credit outstanding principally related to guarantees on contracts and surety bonds outstanding principally related to performance and payment bonds as described in Note 11 of the combined notes to the condensed consolidated financial statements for the three and nine months ended October 31, 2012 contained within this Quarterly Report on Form 10-Q. These arrangements have not had, and management does not believe it is likely that they will in the future have, a material effect on our liquidity, capital resources, operations or financial condition. We have also entered into an agreement with a variable interest entity (VIE) in connection with a renewable energy project as described in Note 11 of the combined notes to the condensed consolidated financial statements for the three and nine months ended October 31, 2012 contained within this Quarterly Report on Form 10-Q.

#### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

#### **Commitments and Contingencies**

We are subject to a number of reviews, investigations, claims, lawsuits and other uncertainties related to our business. For a discussion of these items, see Notes 10 and 11 of the combined notes to the condensed consolidated financial statements for the three and nine months ended October 31, 2012 contained within this Quarterly Report on Form 10-Q.

## **Critical Accounting Policies**

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis. Our estimates and assumptions have been prepared on the basis of the most current reasonably available information. The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates under different assumptions and conditions.

We have several critical accounting policies, which were described in our Annual Report on Form 10-K for the fiscal year ended January 31, 2012, that are both important to the portrayal of our financial condition and results of operations and require management's most difficult, subjective and complex judgments. Typically, the circumstances that make these judgments difficult, subjective and complex have to do with making estimates about the effect of matters that are inherently uncertain. There were no material changes to our critical accounting policies during the nine months ended October 31, 2012.

#### **Non-GAAP Financial Measures**

In this Quarterly Report on Form 10-Q, we refer to internal revenue growth (contraction) percentage, which is a non-GAAP financial measure that we reconcile to the most directly comparable GAAP financial measure. We calculate our internal revenue growth (contraction) percentage by comparing our reported revenues for the current year period to the revenues for the prior year period adjusted to include the actual revenues of acquired businesses for the comparable prior year period before acquisition. This calculation has the effect of adding revenues for the acquired businesses for the comparable prior year period to our prior year period reported revenues.

We use internal revenue growth (contraction) percentage as an indicator of how successful we are at growing our base business and how successful we are at growing the revenues of the businesses that we acquire. Our integration of acquired businesses allows our current management to leverage business development capabilities, drive internal resource collaboration, utilize access to markets and qualifications, and refine strategies to realize synergies, which benefits both acquired and existing businesses. As a result, the performance of the combined enterprise post-acquisition is an important measurement. In addition, as a means of rewarding the successful integration and growth of acquired businesses, and not acquisitions themselves, incentive compensation for our executives and the broader employee population is based, in part, on achievement of revenue targets linked to internal revenue growth.

#### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

The limitation of this non-GAAP financial measure as compared to the most directly comparable GAAP financial measure is that internal revenue growth (contraction) percentage is one of two components of the total revenue growth (contraction) percentage, which is the most directly comparable GAAP financial measure. We address this limitation by presenting the total revenue growth (contraction) percentage next to or near disclosures of internal revenue growth (contraction) percentage. This financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. The method that we use to calculate internal revenue growth (contraction) percentage is not necessarily comparable to similarly titled financial measures presented by other companies. Internal revenue growth (contraction) percentages for the three and nine months ended October 31, 2012 were calculated as follows:

	Three Months Ended October 31, 2012		Nine Months Ended October 31, 2012	
Defense Solutions:		(dollars in	millions)	
Prior year period's revenues, as reported	\$	1.117	\$	3,339
Revenues of acquired businesses for the comparable prior year period	Ψ		Ψ	<b>5,559</b>
Prior year period's revenues, as adjusted	\$	1,117	\$	3,339
Current year period's revenues, as reported	•	1,183	•	3,597
Internal revenue growth	\$	66	\$	258
Internal revenue growth percentage	<u> </u>	6%		8%
Health, Energy and Civil Solutions:				
Prior year period's revenues, as reported	\$	726	\$	1,997
Revenues of acquired businesses for the comparable prior year period		46		127
Prior year period's revenues, as adjusted	\$	772	\$	2,124
Current year period's revenues, as reported		743		2,077
Internal revenue contraction	\$	(29)	\$	(47)
Internal revenue contraction percentage	(4)%		(2)%	
Intelligence and Cybersecurity Solutions:				
Prior year period's revenues, as reported	\$	947	\$	2,691
Revenues of acquired businesses for the comparable prior year period		_		
Prior year period's revenues, as adjusted	\$	947	\$	2,691
Current year period's revenues, as reported		945		2,792
Internal revenue growth (contraction)	\$	(2)	\$	101
Internal revenue growth (contraction) percentage		—%		4%
Total*:				
Prior year period's revenues, as reported	\$	2,790	\$	8,026
Revenues of acquired businesses for the comparable prior year period		46		127
Prior year period's revenues, as adjusted	\$	2,836	\$	8,153
Current year period's revenues, as reported		2,870		8,462
Internal revenue growth	\$	34	\$	309
Internal revenue growth percentage		1%		4%

<sup>\*</sup> Total revenues include amounts related to Corporate and Other and intersegment eliminations.

#### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

#### **Effects of Inflation**

Approximately 40%-50% of our revenues are derived from cost-reimbursement type contracts, which are generally completed within one year. Bids for longer-term FFP and T&M and FP-LOE contracts typically include sufficient provisions for labor and other cost escalations to cover anticipated cost increases over the period of performance. Consequently, revenues and costs have generally both increased commensurate with inflation. As a result, net income as a percentage of total revenues has not been significantly impacted by inflation.

#### Item 3. Quantitative and Qualitative Disclosures About Market Risk.

During the nine months ended October 31, 2012, there were no material changes in our market risk exposure. For a discussion of our market risk associated with interest rate risk and foreign currency risk as of January 31, 2012, see "Quantitative and Qualitative Disclosures about Market Risk" in Part II of our Annual Report on Form 10-K for the fiscal year ended January 31, 2012.

#### Item 4. Controls and Procedures.

#### **Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our principal executive officer (our President and Chief Executive Officer) and principal financial officer (our Executive Vice President and Chief Financial Officer), has evaluated the effectiveness of SAIC's and Science Applications' disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934) as of October 31, 2012, and our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the U.S. Securities and Exchange Commission. These disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

# **Changes In Internal Control Over Financial Reporting**

There have been no changes in our internal control over financial reporting that occurred in the quarterly period covered by this report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

# SAIC, INC. SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

# PART II OTHER INFORMATION

#### Item 1. Legal Proceedings.

We have provided information about legal proceedings in which we are involved in Note 10 of the combined notes to condensed consolidated financial statements for the three and nine months ended October 31, 2012 contained within this Quarterly Report on Form 10-Q.

In addition to the matters disclosed in Note 10, we are routinely subject to investigations and reviews relating to compliance with various laws and regulations, including in connection with contract procurement, award and performance, with respect to our role as a contractor to governmental agencies and departments and in connection with performing services in countries outside of the United States. Adverse findings in these investigations or reviews can lead to criminal, civil or administrative proceedings and we could face penalties, fines, repayments, compensatory damages or suspension or debarment from doing business with governmental agencies. Adverse findings could also have a material adverse effect on our reputation, our business, consolidated financial position, results of operations and cash flows due to our reliance on government contracts.

#### Item 1A. Risk Factors.

Except for the risk factors described below, there were no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2012 and our Quarterly Reports on Form 10-Q for the fiscal guarters ended April 30, 2012 and July 31, 2012.

A decline in the U.S. Government defense budget, changes in spending or budgetary priorities or delays in contract awards may significantly and adversely affect our future revenues and limit our growth prospects.

Revenues under contracts with the DoD, either as a prime contractor or subcontractor to other contractors, represented approximately 75% of our total revenues in fiscal 2012. Our operating results could be adversely affected by spending caps or changes in the budgetary priorities of the U.S. Government or the DoD, as well as delays in program starts or the award of contracts or task orders under contracts. Current U.S. Government spending levels for defense-related programs may not be sustained and future spending and program authorizations may not increase or may decrease or shift to programs in areas in which we do not provide services or are less likely to be awarded contracts. Such changes in spending authorizations and budgetary priorities may occur as a result of the rapid growth of the federal budget deficit, increasing political pressure and legislation, including the Budget Control Act of 2011, designed to reduce overall levels of government spending, shifts in spending priorities from defense-related programs as a result of competing demands for federal funds, the number and intensity of military conflicts or other factors.

The Budget Control Act of 2011 enacted 10-year discretionary spending caps which are expected to generate over \$1 trillion in savings for the U.S. Government, a substantial portion of which comes from DoD baseline spending reductions. In addition, unless the Budget Control Act of 2011 is amended, additional automatic spending cuts (referred to as sequestration) totaling \$1.2 trillion over 10 years will be triggered beginning in the U.S. Government fiscal year ending September 30, 2013 (GFY13). These spending cuts are expected to further reduce DoD and homeland security spending, as well as other federal agency spending. In September 2012, the Office of Management and Budget delivered to Congress a report detailing how sequestration would be implemented. While the report included estimated GFY13 reductions by discretionary budget account, it failed to describe how reductions would occur at levels below the account level (i.e., at the project, program and activity level). As a result, there remains significant uncertainty about how the federal government would implement sequestration, currently set to begin in January 2013. Following the November 2012 elections, while the possibility of sequestration, as well as scheduled tax expirations, and other issues associated with the "fiscal cliff" continue to be the top priority for the Obama Administration and Congress, we cannot predict the outcome of any ongoing discussions to address these matters. In light of the current uncertainty, we are not able to predict the potential impact of possible sequestration on our company or our financial results. However, we expect that implementation of the automatic spending cuts without change will reduce, delay or cancel funding for certain of our contracts and programs and could adversely impact our operations and financial results.

The U.S. Government also conducts periodic reviews of U.S. defense strategies and priorities, which may shift DoD budgetary priorities, reduce overall U.S. Government spending or delay contract or task order awards for defense-related programs, including programs from which we expect to derive a significant portion of our future revenues. In addition, changes to the DoD acquisition system and contracting models could affect whether and how we pursue certain opportunities and the terms under which we are able to do so. A significant decline in overall U.S. Government spending, including in the areas of national security, intelligence and homeland security, a significant shift in its spending priorities, the substantial reduction or elimination of particular defense-related programs or significant delays in contract or task order awards for large programs could adversely affect our future revenues and limit our growth prospects.

#### SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

# Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

# (c) Purchases of Equity Securities by the Company

In March 2012, our board of directors authorized a stock repurchase program under which we may repurchase up to 40 million shares of SAIC common stock (the 2012 Repurchase Program). Stock repurchases may be made on the open market or in privately negotiated transactions with third-parties. Whether repurchases are made and the timing and actual number of shares repurchased depends on a variety of factors including price, corporate capital requirements, other market conditions and regulatory requirements.

The following table presents repurchases of SAIC common stock during the quarter ended October 31, 2012:

			(c)	
			Total Number of	(d)
			Shares (or	Maximum Number
			Units)	(or Approximate
			Purchased as	Dollar Value) of
	(a)		Part of Publicly	Shares (or Units)
	Total Number of	(b)	Announced	that May Yet Be
	Shares	Average Price	Repurchase	Purchased Under
	(or Units) Purchased <sup>(1)</sup>	Paid per Share	_Plans or	the Plans or
Period	Purchased (±)	(or Unit)	Programs	Programs <sup>(2)</sup>
August 1, 2012 – August 31, 2012	8,792	\$ 11.60	_	40,000,000
September 1, 2012 – September 30, 2012	46,475	12.30		40,000,000
October 1, 2012 – October 31, 2012	31,491	11.93	_	40,000,000
Total	86,758	12.09	_	

<sup>(1)</sup> Includes shares purchased as follows:

	August	September	October
Upon surrender by stockholders of previously owned shares to satisfy statutory tax withholding			
obligations related to vesting of stock awards	8,792	46,475	31,491

We may repurchase up to 40 million shares of SAIC common stock under the 2012 Repurchase Program, which was publicly announced in March 2012.

#### Item 3. Defaults Upon Senior Securities.

None.

#### Item 4. Mine Safety Disclosures.

Not applicable.

### Item 5. Other Information.

None.

# Item 6. Exhibits.

Exhibit Number	Description of Exhibit
10.1	Administrative Agreement between Science Applications International Corporation and the United States Army on behalf of the U.S. Government, dated August 21, 2012. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K as filed on August 21, 2012 with the SEC.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	Interactive Data File.

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, each registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 5, 2012

SAIC, Inc.

/s/ MARK W. SOPP

Mark W. Sopp Executive Vice President and Chief Financial Officer and as a duly authorized officer

Date: December 5, 2012

Science Applications International Corporation

/s/ MARK W. SOPP

Mark W. Sopp Executive Vice President and Chief Financial Officer and as a duly authorized officer

# SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

# **Exhibit Index**

Exhibit Number	Description of Exhibit
10.1	Administrative Agreement between Science Applications International Corporation and the United States Army on behalf of the U.S. Government, dated August 21, 2012. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K as filed on August 21, 2012 with the SEC.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	Interactive Data File.

# SAIC, INC. AND SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

#### I, John P. Jumper, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q for the period ended October 31, 2012 of SAIC, Inc. and Science Applications International Corporation;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrants as of, and for, the periods presented in this report;
- 4. The registrants' other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrants and have:
  - Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrants, including each registrants' consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - Evaluated the effectiveness of the registrants' disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrants' internal control over financial reporting that occurred during the registrants' most recent fiscal quarter (the registrants' fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants' internal control over financial reporting; and
- 5. The registrants' other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants' auditors and the audit committee of the registrants' board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants' ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants' internal control over financial reporting.

Date: December 5, 2012

/s/ JOHN P. JUMPER

John P. Jumper

Chairman and Chief Executive Officer

# SAIC, INC. AND SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

#### I, Mark W. Sopp, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q for the period ended October 31, 2012 of SAIC, Inc. and Science Applications International Corporation;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrants as of, and for, the periods presented in this report;
- 4. The registrants' other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrants and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrants, including each registrants' consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:
  - Evaluated the effectiveness of the registrants' disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrants' internal control over financial reporting that occurred during the registrants' most recent fiscal quarter (the registrants' fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants' internal control over financial reporting; and
- 5. The registrants' other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants' auditors and the audit committee of the registrants' board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants' ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants' internal control over financial reporting.

Date: December 5, 2012

/S/ MARK W. SOPP

Mark W. Sopp

Chief Financial Officer

### SAIC, INC. AND SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of SAIC, Inc. ("SAIC") and Science Applications International Corporation ("Science Applications", and together with SAIC, the "Company") on Form 10-Q for the period ended October 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John P. Jumper, Chief Executive Officer and President of each of SAIC and Science Applications, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: December 5, 2012

/s/ JOHN P. JUMPER

John P. Jumper Chairman and Chief Executive Officer

### SAIC, INC. AND SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of SAIC, Inc. ("SAIC") and Science Applications International Corporation ("Science Applications", and together with SAIC, the "Company") on Form 10-Q for the period ended October 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Mark W. Sopp, Chief Financial Officer of each of SAIC and Science Applications, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	December	5,	2012
-------	----------	----	------

/s/ Mark W. Sopp

Mark W. Sopp Chief Financial Officer